US20060198790A1 - Buccal, polar and non-polar spray containing ondansetron - Google Patents
Buccal, polar and non-polar spray containing ondansetron Download PDFInfo
- Publication number
- US20060198790A1 US20060198790A1 US11/429,953 US42995306A US2006198790A1 US 20060198790 A1 US20060198790 A1 US 20060198790A1 US 42995306 A US42995306 A US 42995306A US 2006198790 A1 US2006198790 A1 US 2006198790A1
- Authority
- US
- United States
- Prior art keywords
- amount
- composition
- percent
- weight
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- UFZDONOTASUATM-UHFFFAOYSA-N CC1=CC=CN1CC1CCC2=C(C1=O)C1=CC=CC=C1N2C Chemical compound CC1=CC=CN1CC1CCC2=C(C1=O)C1=CC=CC=C1N2C UFZDONOTASUATM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- a chewable gelatin capsule containing a solution or dispersion of a drug is described in U.S. Pat. No. 4,935,243, Borkan et al.
- U.S. Pat. No. 4,919,919, Aouda et al, and U.S. Pat. No. 5,370,862, Klokkers-Bethke describe a nitroglycerin spray for administration to the oral mucosa comprising nitroglycerin, ethanol, and other components.
- An orally administered pump spray is described by Cholcha in U.S. Pat. No. 5,186,925.
- Aerosol compositions containing a hydrocarbon propellant and a drug for administration to a mucosal surface are described in U.K.
- Ondansetron is a 5-HT 3 receptor antagonist.
- the structure of ondansetron is depicted below:
- Ondansetron is an anti-emetic used to treat nausea and/or vomiting, especially chemotherapy and radiation induced nausea and/or vomiting ( Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9 th ed., pp. 260). Ondansetron is also used as a pre-operative anti-emetic ( Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9 th ed., pp. 304). Administration of ondansetron in combination with a corticosteroid, such as phenothiazine or butyrophenone, can increase efficacy as an anti-emetic ( Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9 th ed., pp. 928). Ondansetron can also be used to treat anxiety ( Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9 th ed., pp. 427).
- Ondansetron can be administered orally, intravenously, or intramuscularly.
- Ondansetron when administered as an anti-emetic for severe chemotherapy-induced emesis, is typically administered at a single daily dose of 32 mg by intravenous infusion over about 15 minutes about 30 minutes prior to chemotherapy or intravenously in 3 divided doses of 0.1 to 0.15 mg/kg with the first dose given about 30 minutes prior to chemotherapy and the following doses given 4 and 8 hours after the initial dose.
- ondansetron can be administered at a daily dose of 32 mg in combination with a daily dose of 20 mg dexamethasone, each administered by intravenous infusion.
- ondansetron is typically administered orally (as a tablet or solution) at a dose of 8 mg (tablet) or 10 mg (solution) about 30 minutes prior to chemotherapy followed by a second dose 8 hours later. The dose can then be repeated twice per day for 1 to 2 days following chemotherapy ( Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9 th ed., pp. 928-930).
- ondansetron The oral bioavailability of ondansetron is about 60 percent with effective blood levels appearing 30 to 60 minutes after administration. Ondansetron is extensively metabolized by the liver with a plasma half-life of about 3 to 4 hours. Adverse effects of ondansetron are mild and include headaches, constipation, and dizziness ( Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9 th ed., pp. 928-930).
- a buccal aerosol spray or soft bite gelatin capsule using a polar or non-polar solvent has now been developed which provides biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect.
- the composition comprises: propellant 10-70%, non-polar solvent 25-89.9%, active compound 0.01-40%, flavoring agent 1-8%; most suitably propellant 20-70%, non-polar solvent 25-74.75%, active compound 0.25-35%, flavoring agent 2-7.5%.
- compositions of the present invention for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent are also administrable in aerosol form driven by a propellant.
- the composition comprises in weight % of total composition: aqueous polar solvent 10-97%, active compound 0.1-25%, suitably additionally comprising, by weight of total composition a flavoring agent 0.05-10% and propellant: 2-10%.
- the composition comprises: polar solvent 20-97%, active compound 0.1-15%, flavoring agent 0.1-5% and propellant 2-5%; most suitably polar solvent 25-97%, active compound 0.2-25%, flavoring agent 0.1-2.5% and propellant 2-4%.
- the buccal polar aerosol spray compositions of the present invention for transmucosal administration of a pharmacologically active compound comprises a mixture of a polar solvent and a non-polar solvent comprising in weight % of total composition: solvent 10-97%, active compound 0.05-50%, propellant 5-80%, and optionally a taste mask and/or flavoring agent 0.01-10%.
- the composition comprises: solvent 20-97%, active compound 0.1-40%, propellant 10-70%, and taste mask and/or flavoring agent 1-8%; most suitably solvent 25-97%, active compound 0.25-35%, propellant 20-70%, and taste mask and/or flavoring agent 2-7.5%.
- the ratio of the polar solvent to the non-polar solvent can range from about 1:99 to about 99:1, preferable from about 60:40 to about 40:60, and more preferably about 50:50.
- the buccal pump spray composition of the present invention i.e., the propellant free composition, for transmucosal administration of a pharmacologically active compound wherein said active compound is soluble in a pharmacologically acceptable non-polar solvent comprises in weight % of total composition: non-polar solvent 30-99.69%, active compound 0.005-55%, and suitably additionally, flavoring agent 0.1-10%.
- the composition comprises: polar solvent 37-98.58%, active compound 0.005-55%, flavoring agent 0.5-8%; most suitably polar solvent 60.9-97.06%, active compound 0.01-40%, flavoring agent 0.75-7.5%.
- the composition comprises: solvent 37-98.58%, active compound 0.005-55%, taste mask and/or flavoring agent 0.5-8%; more preferably the composition comprises solvent 60.9-97.06%, active compound 0.01-40%, and taste mask and/or flavoring agent 0.75-7.5%.
- the ratio of the polar solvent to the non-polar solvent can range from about 1:99 to about 99:1, preferable about 60:40 to about 40:60, and more preferably about 50:50.
- the soft bite gelatin capsules of the present invention for transmucosal administration of a pharmacologically active compound, at least partially soluble in a pharmacologically acceptable non-polar solvent, having charged thereto a fill composition comprise in weight % of total composition: non-polar solvent 4-99.99%, emulsifier 0-20%, active compound 0.01-80%, provided that said fill composition contains less than 10% of water, suitably additionally comprising, by weight of the composition: flavoring agent 0.01-10%.
- the soft bite gelatin capsule comprises: non-polar solvent 21.5-99.975%, emulsifier 0-15%, active compound 0.025-70%, flavoring agent 1-8%; most suitably: nonpolar solvent 28.5-97.9%, emulsifier 0-10%, active compound 0.1-65.0%, flavoring agent 2-6%.
- the soft bite gelatin capsule comprises: polar solvent 37-99.95%, emulsifier 0-15%, active compound 0.025-55%, flavoring agent 1-8%; most suitably: polar solvent 44-96.925%, emulsifier 0-10%, active compound 0.075-50%, flavoring agent 2-6%.
- a further object is a sealed aerosol spray container containing a composition of the non polar or polar aerosol spray formulation, and a metered valve suitable for releasing from said container a predetermined amount of said composition.
- the propellant is a non-Freon material, preferably a C 3-8 hydrocarbon of a linear or branched configuration.
- the propellant should be substantially non-aqueous.
- the propellant produces a pressure in the aerosol container such that under expected normal usage it will produce sufficient pressure to expel the solvent from the container when the valve is activated but not excessive pressure such as to damage the container or valve seals.
- the non-polar solvent is a non-polar hydrocarbon, preferably a C 7-18 hydrocarbon of a linear or branched configuration, fatty acid esters, and triglycerides, such as miglyol.
- the solvent must dissolve the active compound and be miscible with the propellant, i.e., solvent and propellant must form a single phase at a temperature of 0-40° C. a pressure range of between 1-3 atm.
- the polar and non-polar aerosol spray compositions of the invention are intended to be administered from a sealed, pressurized container. Unlike a pump spray, which allows the entry of air into the container after every activation, the aerosol container of the invention is sealed at the time of manufacture. The contents of the container are released by activation of a metered valve, which does not allow entry of atmospheric gasses with each activation.
- a metered valve which does not allow entry of atmospheric gasses with each activation.
- a further object is a pump spray container containing a composition of the pump spray formulation, and a metered valve suitable for releasing from said container a predetermined amount of said composition.
- a further object is a soft gelatin bite capsule containing a composition of as set forth above.
- the formulation may be in the form of a viscous solution or paste containing the active compounds. Although solutions are preferred, paste fills may also be used where the active compound is not soluble or only partially soluble in the solvent of choice. Where water is used to form part of the paste composition, it should not exceed 10% thereof. (All percentages herein are by weight unless otherwise indicated.)
- the polar or non-polar solvent is chosen such that it is compatible with the gelatin shell and the active compound.
- the solvent preferably dissolves the active compound.
- other components wherein the active compound is not soluble or only slightly soluble may be used and will form a paste fill.
- Soft gelatin capsules are well known in the art. See, for example, U.S. Pat. No. 4,935,243, Borkan et al., for its teaching of such capsules.
- the capsules of the present invention are intended to be bitten into to release the low viscosity solution or paste therein, which will then coat the buccal mucosa with the active compounds.
- the shell of a soft gelatin capsule of the invention may comprise, for example: gelatin: 50-75%, glycerin 20-30%, colorants 0.5-1.5%, water 5-10%, and sorbitol 2-10%.
- the active compound may include, biologically active peptides, central nervous system active amines, sulfonyl ureas, antibiotics, antifungals, antivirals, sleep inducers, antiasthmatics, bronchial dilators, antiemetics, histamine H-2 receptor antagonists, barbiturates, prostaglandins and neutraceuticals.
- the active compounds may also include antihistamines, alkaloids, hormones, benzodiazepines and narcotic analgesics. While not limited thereto, these active compounds are particularly suitable for non-polar pump spray formulation and application.
- the active compounds may also include anti-diuretics, anti-muscle spasm agents, anti-spasmodics, agents for treating urinary incontinence, anti-diarrheal agents, agents for treating nausea and/or vomiting, smooth muscle contractile agents, anti-secretory agents, enzymes, anti-diuretics, anti-ulcerants, bile acid replacement and/or gallstone solubilizing drugs, or mixtures thereof.
- the active compound is ondansetron or a pharmaceutically acceptable salt thereof.
- FIG. 1 is a schematic diagram showing routes of absorption and processing of pharmacologically active substances in a mammalian system.
- the preferred active compounds of the present invention are in an ionized, salt form or as the free base of the pharmaceutically acceptable salts thereof (provided, for the aerosol or pump spray compositions, they are soluble in the spray solvent). These compounds are soluble in the non-polar solvents of the invention at useful concentrations or can be prepared as pastes at useful concentrations. These concentrations may be less than the standard accepted dose for these compounds since there is enhanced absorption of the compounds through the oral mucosa. This aspect of the invention is especially important when there is a large (40-99.99%) first pass effect.
- propellants for the non polar sprays propane, N-butane, iso-butane, N-pentane, iso-pentane, and neo-pentane, and mixtures thereof may be used.
- N-butane and iso-butane, as single gases, are the preferred propellants. It is permissible for the propellant to have a water content of no more than 0.2%, typically 0.1-0.2%. All percentages herein are by weight unless otherwise indicated. It is also preferable that the propellant be synthetically produced to minimize the presence of contaminants which are harmful to the active compounds. These contaminants include oxidizing agents, reducing agents, Lewis acids or bases, and water. The concentration of each of these should be less than 0.1%, except that water may be as high as 0.2%.
- Suitable non-polar solvents for the capsules and the non-polar sprays include (C 2 -C 24 ) fatty acid (C 2 -C 6 ) esters, C 7 -C 18 hydrocarbon, C 2 -C 6 alkanoyl esters, and the triglycerides of the corresponding acids.
- other liquid components may be used instead of the above low molecular weight solvents. These include soya oil, corn oil, other vegetable oils.
- solvents for the polar capsules or sprays there may be used low molecular weight polyethyleneglycols (PEG) of 400-1000 Mw (preferably 400-600), low molecular weight (C 2 -C 8 ) mono and polyols and alcohols of C 7 -C 18 linear or branch chain hydrocarbons, glycerin may also be present and water may also be used in the sprays, but only in limited amount in the capsules.
- PEG polyethyleneglycols
- C 2 -C 8 low molecular weight mono and polyols and alcohols of C 7 -C 18 linear or branch chain hydrocarbons
- glycerin may also be present and water may also be used in the sprays, but only in limited amount in the capsules.
- the preferred flavoring agents are synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners (sugars, aspartame, saccharin, etc.), and combinations thereof.
- compositions may further include a taste mask.
- taste mask as used herein means an agent that can hide or minimize an undesirable flavor such as a bitter or sour flavor.
- a representative taste mask is a combination of vanillin, ethyl vanillin, maltol, iso-amyl acetate, ethyl oxyhydrate, anisic aldehyde, and propylene glycol (commercially available as “PFC 9885 Bitter Mask” from Pharmaceutical Flavor Clinic of Camden, N.J.).
- a taste mask in combination with a flavoring agent is particularly advantageous when the active compound is an alkaloid since alkaloids often have a bitter taste.
- the active substances include the active compounds selected from the group consisting of cyclosporine, sermorelin, octreotide acetate, calcitonin-salmon, insulin lispro, sumatriptan succinate, clozepine, cyclobenzaprine, dexfenfluramine hydrochloride, glyburide, zidovudine, erythromycin, ciprofloxacin, ondansetron hydrochloride, dimenhydrinate, cimetidine hydrochloride, famotidine, phenyloin sodium, phenyloin, carboprost thromethamine, carboprost, diphenhydramine hydrochloride, isoproterenol hydrochloride, terbutaline sulfate, terbutaline, theophylline, albuterol sulfate and neutraceuticals, that is to say nutrients with pharmacological action such as but not limited to carnitine,
- the active compound is an anti-diuretic, anti-muscle spasm agent, anti-spasmodic, agent for treating urinary incontinence, anti-diarrheal agent, agent for treating nausea and/or vomiting, smooth muscle contractile agent, anti-secretory agent, enzyme, anti-diuretic, anti-ulcerant, bile acid replacement and/or gallstone solubilizing drug, or a mixture thereof.
- the active compound is an anti-diuretic.
- Suitable anti-diuretics for use in the buccal sprays of the invention include, but are not limited to, acetazolamide, benzthiazide, bendroflumethazide, bumetamide, chlorthalidone, chlorothiazide, ethacrynic acid, furosemide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, quinethazone, spironolactone, triamterene, torsemide, trichlomethiazide, and mixtures thereof.
- the active compound is an anti-muscle spasm agent.
- Suitable anti-muscle spasm agents for use in the buccal sprays of the invention include, but are not limited to, baclofen, botulinum toxin, carisoprodol, chlorphenesin, chlorzoxazone, cyclobenzaprine, dantrolene, diazepam, metaxalone, methocarbamol, orphenadrine, tizanidine, and mixtures thereof.
- the active compound is an anti-spasmodic.
- Suitable anti-spasmodics for use in the buccal sprays of the invention include, but are not limited to, atropine, baclofen, dicyclomine, hyoscine, propatheline, oxybutynin, S-oxybutynin, tizanidine, and mixtures thereof.
- the active compound is an agent for treating urinary incontinence.
- Suitable agents for treating urinary incontinence for use in the buccal sprays of the invention include, but are not limited to, darifenacin, vamicamide, detrol, ditropan, imipramine, and mixtures thereof.
- the active compound is an anti-diarrheal agent.
- Suitable anti-diarrheal agents for use in the buccal sprays of the invention include, but are not limited to, ondansetron, palnosetron, tropisetron, attapulgite, atropine, bismuth, diphenoxylate, loperamide, and mixtures thereof.
- the active compound is an agent for treating nausea and/or vomiting.
- Suitable agents for treating nausea and/or vomiting for use in the buccal sprays of the invention include, but are not limited to, alosetron, dolasetron, granisetron, meclizine, metoclopramide, ondansetron, palnosetron, prochloperazine, promethazine, trimethobenzamiode, tropisetron, and mixtures thereof.
- the active compound is a smooth muscle contractile agent.
- a suitable smooth muscle contractile agents for use in the buccal sprays of the invention includes, but is not limited to hyoscine.
- the active compound is an anti-secretory agent.
- Suitable anti-secretory agents for use in the buccal sprays of the invention include, but are not limited to, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, tenetoprazole, ecabet, misoprostol, teprenone, and mixtures thereof.
- the active compound is an enzyme.
- Suitable enzymes for use in the buccal sprays of the invention include, but are not limited to, alpha-galactosidase, alpha-L-iduronidase, imiglucerase/alglucerase, anylase, lipase, protease, pancreatin, olsalazine, and mixtures thereof.
- the active compound is an anti-diuretic.
- Suitable anti-diuretics for use in the buccal sprays of the invention include, but are not limited to, desmopressin, oxytocin, and mixtures thereof.
- the active compound is an anti-ulcerant.
- Suitable anti-ulcerants for use in the buccal sprays of the invention include, but are not limited to, cimetidine, ranitidine, famotidine, misoprostol, sucralfate, pantoprazole, lansoprazole, omeprazole, and mixtures thereof.
- the active compound is a bile acid replacement and/or gallstone solubilizing drug.
- a suitable bile acid replacement and/or gallstone solubilizing drug for use in the buccal sprays of the invention includes, but is not limited to ursodiol.
- the active compound is ondansetron, or a pharmaceutically acceptable salt thereof. In one embodiment, the active compound is ondansetron hydrochloride.
- the buccal spray contains from about contains form about 0.01 to 20 weight/weight (w/w) percent ondansetron, or a pharmaceutically acceptable salt thereof, preferably, about 0.1 to 15 w/w percent, and more preferably about 0.2 to 10 w/w percent ondansetron, or a pharmaceutically acceptable salt thereof.
- the invention further relates to a method for treating emesis in a patient by spraying the oral mucosa of the patient with a therapeutically effective amount of a buccal spray comprising ondansetron or a pharmaceutically acceptable salt thereof.
- the emesis is chemotherapy induced emesis.
- the emesis is radiation induced emesis.
- the ondansetron or a pharmaceutically acceptable salt thereof, is administered in combination with a corticosteroid, such as phenothiazine or butyrophenone.
- a corticosteroid such as phenothiazine or butyrophenone.
- the ondansetron or a pharmaceutically acceptable salt thereof, is administered in combination with dexamethasone.
- the oral mucosa of the patient is sprayed with ondansetron, or a pharmaceutically acceptable salt thereof, before chemotherapy or radiation therapy begins.
- ondansetron, or a pharmaceutically acceptable salt thereof is sprayed on the oral mucosa of the patient between about 5 minutes and about 2 hours before chemotherapy or radiation therapy begins, preferably between about 15 minutes and about 1 hour, more preferably between about 30 minutes before chemotherapy or radiation therapy begins.
- the method further includes administering ondansetron, or a pharmaceutically acceptable salt thereof, after chemotherapy or radiation therapy is ended.
- the ondansetron, or a pharmaceutically acceptable salt thereof is sprayed on the oral mucosa of the patient between about 1 hour and 6 hours after chemotherapy or radiation therapy has ended, preferable between about 2 hours and about 5 hours, more preferably about 4 hours after chemotherapy or radiation therapy has ended.
- the emesis is anesthetic induced emesis. Accordingly, the invention further relates to a method of administering anesthesia by spraying the oral mucosa of the patient with a therapeutically effective amount of a buccal spray comprising ondansetron or a pharmaceutically acceptable salt thereof before the anesthesis is administered.
- the invention further relates to a method for treating anxiety in a patient by spraying the oral mucosa of the patient with a therapeutically effective amount of a buccal spray comprising ondansetron or a pharmaceutically acceptable salt thereof.
- compositions of the present invention comprise an active compound or a pharmaceutically acceptable salt thereof.
- pharmaceutically acceptable salts refer to salts prepared from pharmaceutically acceptable non-toxic acids or bases including organic and inorganic acids or bases.
- salts may be prepared from pharmaceutically acceptable non-toxic bases.
- Salts derived from all stable forms of inorganic bases include aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, zinc, etc. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins such as arginine, betaine, caffeine, choline, N,N dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethyl-aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methyl-glucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, etc.
- basic ion-exchange resins such as arginine, betaine, caffeine, choline
- salts may be prepared from pharmaceutically acceptable non-toxic acids.
- acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethane-sulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, etc.
- Particularly preferred are citric, hydrobromic, maleic, phosphoric, sulfuric, and tartaric acids.
- Cyclosporine Lingual Spray preferred most preferred Amounts amount amount amount cyclosporine 5-50 10-35 15-25 water 5-20 7.5-50 9.5-12 ethanol 5-60 7.5-50 10-20 polyethylene glycol 20-60 30-45 35-40 flavors 0.1-5 1-4 2-3
- Cyclosporine Non-Polar Lingual Spray preferred most preferred Amounts amount amount amount cyclosporine 1-50 3-40 5-30 Migylol 20 25 30-40 Polyoxyethylated castor oil 20 25 30-40 Butane 25-80 30-70 33-50 flavors 0.1-5 1-4 2-3
- Cyclosporine Non-Polar Bite Caosule preferred most preferred Amounts amount amount cyclosporine 1-35 5-25 10-20 olive oil 25-60 35-55 30-45 polyoxyethylated 25-60 35-55 30-45 oleic glycerides flavors 0.1-5 1-4 2-3
- Calcitonin-Salmon Lingual Spray preferred most preferred Amounts amount amount calcitonin-salmon 0.001-5 0.005-2 01-1.5 ethanol 2-15 3-10 7-9.5 water 30-95 50-90 60-80 polyethylene 2-15 3-10 7-9.5 glycol sodium chloride 2.5-20 5-15 10-12.5 flavors 0.1-5 1-4 2-3
- CNS Active Amines and Their Salts Including but not Limited to Tricyclic Amines, GABA Analogues, Thiazides, Phenothiazine Derivatives, Serotonin Antagonists and Serotonin Reuptake Inhibitors
- Sumatriptan Succinate Lingual Spray preferred most preferred Amounts amount amount amount sumatriptan succinate 0.5-30 1-20 10-15 ethanol 5-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 5-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3
- Clozepine Lingual Spray preferred most preferred Amounts amount amount amount clozepine 0.5-30 1-20 10-15 ethanol 5-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 5-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3
- Clozepine Non-Polar Lingual Spray with Propellant preferred most preferred Amounts amount amount amount clozepine 0.5-30 1-20 10-15 Migylol 20-85 25-70 30-40 Butanol 5-80 30-75 60-70 flavors 0.1-5 1-4 2-3
- Cyclobenzaprine Non-Polar Lingual Spray preferred most preferred Amounts amount amount amount cyclobenzaprine (base) 0.5-30 1-20 10-15 Migylol 20-85 25-70 30-40 Iso-butane 15-80 30-75 60-70 flavors 0.1-5 1-4 2-3
- Dexfenfluramine Hydrochloride Lingual Spray preferred most preferred Amounts amount amount amount dexfenfluramine Hcl 5-30 7.5-20 10-15 ethanol 5-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 5-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3
- Glyburide Lingual Spray preferred most preferred Amounts amount amount amount glyburide 0.25-25 0.5-20 0.75-15 ethanol 5-60 ⁇ 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 2.5-30 5-20 6-15 flavors 0.1-5 1-4 2-3
- Glyburide Non-Polar Bite Capsule preferred most preferred Amounts amount amount amount glyburide 0.01-10 0.025-7.5 0.1-4 olive oil 30-60 35-55 30-50 polyoxyethylated oleic 30-60 35-55 30-50 glycerides flavors 0.1-5 1-4 2-3
- Zidovudine Formly Called Azidothymidine (AZT) (Retrovir)
- Non-Polar Lingual Spray preferred most preferred Amounts amount amount zidovudine 10-50 15-40 25-35 Soya oil 20-85 25-70 30-40 Butane 15-80 30-75 60-70 flavors 0.1-5 1-4 2-3
- Zidovudine [Formerly Called Azidothymidine (AZT) (Retrovir)] Lingual Spray preferred most preferred Amounts amount amount zidovudine 10-50 15-40 25-35 water 30-80 40-75 45-70 ethanol 5-20 7.5-15 9.5-12.5 polyethylene glycol 5-20 7.5-15 9.5-12.5 flavors 0.1-5 1-4 2-3
- a Propellant Free Ondansetron Formulation in a Polar Solvent can be made according to the following Formula: Component Percent (w/w) Ondansetron Hydrochloride 4 Tween 80 0.5 EDTA 0.02 Ethanol 10 Glycerol 5 Water QS to 100
- a propellant Free Ondansetron Formulation in a Non-Polar Solvent can be made according to the following Formula Component Percent (w/w) Ondansetron 0.2 Bitter Mask 0.50.1 Alpha-tocopherol Acetate 2 Liquid Paraffin QS to 100
- a Propellant Free Ondansetron Formulation in a Mixture of a Polar Solvent and a Non-Polar Solvent can be made according to the following Formula Component Percent (w/w) Ondansetron 0.1 Miglyol 810 20 Polysorbate (span) 1 Lemon Oil 0.1 Ethanol QS to 100
- An Ondansetron Formulation in a Non-Polar Solvent with a Propellant can be made according to the following Formula: Component Percent (w/w) Ondansetron 0.1 Lemon Oil 0.2 Miglyol 20 Butane 100
- An Ondansetron Formulation in a Polar Solvent with a Propellant can be made according to the following Formula: Component Percent (w/w) Ondansetron 2 Bitter mask 0.2 Ethanol 60 Butane 100
- An Ondansetron Formulation in a Mixture of a Polar Solvent and a Non-Polar Solvent with a Propellant can be made according to the following Formula: Component Percent (w/w) Ondansetron 0.1 Miglyol 20 Polysorbate (span) 1 Lemon Oil 0.1 Ethanol 20 Butane 100
- Dimenhydrinate Polar Lingual Spray preferred most preferred Amounts amount amount dimenhydrinate 3-50 4-40 5-35 water 5-90 10-80 15-75 ethanol 1-80 3-50 5-10 polyethylene glycol 1-80 3-50 5-15 sorbitol 0.1-5 0.2-40 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3
- Famotidine Lingual Spray preferred most preferred Amounts amount amount amount famotidine 1-35 5-30 7-20 water 2.5-25 3-20 5-10 L-aspartic acid 0.1-20 1-15 5-10 polyethylene glycol 20-97 30-95 50-85 flavors 0.1-10 1-7.5 2-5
- Famotidine Non-Polar Lingual Spray preferred most preferred Amounts amount amount amount famotidine 1-35 5-30 7-20 Soya oil 10-50 15-40 15-20 Butane1 5-80 30-75 45-70 polyoxyethylated 10-50 15-40 15-20 oleic glycerides flavors 0.1-5 1-4 2-3
- Phenytoin Sodium Lingual Spray preferred most preferred Amounts amount amount amount phenytoin sodium 10-60 15-55 20-40 water 2.5-25 3-20 5-10 ethanol 5-30 7.5-20 9.5-15 propylene glycol 5-30 7.5-20 9.5-15 polyethylene glycol 5-30 7.5-20 9.5-15 flavors 1-10 3-8 5-7.5
- Phenytoin Non-Polar Lingual Spray preferred most preferred Amounts amount amount amount phenytoin 5-45 10-40 15-35 migylol 10-50 15-40 15-20 Butane 15-80 30-75 60-70 polyoxyethylated 10-50 15-40 15-20 oleic glycerides flavors 0.1-10 1-8 5-7.5
- Carboprost Non-Polar Lingual Spray preferred most preferred Amounts amount amount amount carboprost 0.05-5 0.1-3 0.25-2.5 migylol 25-50 30-45 35-40 Butane 5-60 10-50 20-35 polyoxyethylated 25-50 30-45 35-40 oleic glycerides flavors 0.1-10 1-8 5-7.5
- Valerian as Lingual Spray preferred most preferred Amounts amount amount valerian extract 0.1-10 0.2-7 0.25-5 water 50-95 60-80 65-75 ethanol 5-20 7.5-15 9.5-12.5 polyethylene glycol 5-20 7.5-15 9.5-12.5 flavors 1-10 2-8 3-6
- Echinacea as Bite Capsule preferred most preferred Amounts amount amount echinacea extract 30-85 40-75 45-55 soya oil 7.5-50 10-40 12.5-35 soya lecithin 0.001-1.0 0.005-0.5 .01-0.1 Soya fats 7.5-50 10-40 12.5-35 flavors 1-10 2-8 3-6
- Isoproterenol Hydrochloride as Polar Lingual Spray preferred most preferred Amounts amount amount isoproterenol Hydrochloride 0.1-10 0.2-7.5 0.5-6 water 5-90 10-80 50-75 ethanol 1-80 3-50 5-10 polyethylene glycol 1-80 3-50 5-15 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3
- terbutaline 0.1-10 0.2-7.5 0.5-6 migylol 25-50 30-45 35-40 isobutane 5-60 10-50 20-35 polyoxyethylated 25-50 30-45 35-40 oleic glycerides flavors 0.1-10 1-8 5-7.5
- Theophylline Polar Bite Capsule preferred most preferred Amounts amount amount theophylline 5-50 10-40 15-30 polyethylene glycol 20-60 25-50 30-40 glycerin 25-50 35-45 30-40 propylene glycol 25-50 35-45 30-40 flavors 0.1-5 1-4 2-3
- Albuterol Sulfate as Polar Lingual Spray preferred most preferred Amounts amount amount amount albuterol sulfate 0.1-10 0.2-7.5 0.5-6 water 5-90 10-80 50-75 ethanol 1-10 2-8 2.5-5 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3
- Prostaglandin E vadilator
- Promethazine Antiemetic, Sleep Inducer, and CNS Active Amine
Abstract
Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, ondansetron, and optional flavoring agent; formulation II: aqueous polar solvent, ondansetron, optionally flavoring agent, and propellant; formulation III: non-polar solvent, ondansetron, and optional flavoring agent; formulation IV: non-polar solvent, ondansetron, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, ondansetron, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, ondansetron, optional flavoring agent, and propellant.
Description
- This application is a continuation-in-part of application Ser. No. 10/230,085, filed Aug. 29, 2002, now pending, which is a continuation-in-part of application Ser. No. 09/537,118, filed Mar. 29, 2000 which is a continuation-in-part of the U.S. national phase designation of PCT/US97/17899 filed Oct. 1, 1997, the disclosures of which are incorporated by reference herein in their entirety.
- It is known that certain biologically active compounds are better absorbed through the oral mucosa than through other routes of administration, such as through the stomach or intestine. However, formulations suitable for such administration by these latter routes present their own problems. For example, the biologically active compound must be compatible with the other components of the composition such as propellants, solvents, etc. Many such formulations have been proposed. For example, U.S. Pat. No. 4,689,233, Dvorsky et al., describes a soft gelatin capsule for the administration of the anti-coronary drug nifedipine dissolved in a mixture of polyether alcohols. U.S. Pat. No. 4,755,389, Jones et al., describes a hard gelatin chewable capsule containing nifedipine. A chewable gelatin capsule containing a solution or dispersion of a drug is described in U.S. Pat. No. 4,935,243, Borkan et al. U.S. Pat. No. 4,919,919, Aouda et al, and U.S. Pat. No. 5,370,862, Klokkers-Bethke, describe a nitroglycerin spray for administration to the oral mucosa comprising nitroglycerin, ethanol, and other components. An orally administered pump spray is described by Cholcha in U.S. Pat. No. 5,186,925. Aerosol compositions containing a hydrocarbon propellant and a drug for administration to a mucosal surface are described in U.K. 2,082,457, Su, U.S. Pat. No. 3,155,574, Silson et al., U.S. Pat. No. 5,011,678, Wang et al., and by Parnell in U.S. Pat. No. 5,128,132. It should be noted that these references discuss bioavailability of solutions by inhalation rather than through the membranes to which they are administered.
-
- Ondansetron is an anti-emetic used to treat nausea and/or vomiting, especially chemotherapy and radiation induced nausea and/or vomiting (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 260). Ondansetron is also used as a pre-operative anti-emetic (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 304). Administration of ondansetron in combination with a corticosteroid, such as phenothiazine or butyrophenone, can increase efficacy as an anti-emetic (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 928). Ondansetron can also be used to treat anxiety (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 427).
- Ondansetron can be administered orally, intravenously, or intramuscularly. Ondansetron, when administered as an anti-emetic for severe chemotherapy-induced emesis, is typically administered at a single daily dose of 32 mg by intravenous infusion over about 15 minutes about 30 minutes prior to chemotherapy or intravenously in 3 divided doses of 0.1 to 0.15 mg/kg with the first dose given about 30 minutes prior to chemotherapy and the following doses given 4 and 8 hours after the initial dose. To treat severe chemotherapy-induced emesis, ondansetron can be administered at a daily dose of 32 mg in combination with a daily dose of 20 mg dexamethasone, each administered by intravenous infusion. For moderate chemotherapy-induced emesis, ondansetron is typically administered orally (as a tablet or solution) at a dose of 8 mg (tablet) or 10 mg (solution) about 30 minutes prior to chemotherapy followed by a second dose 8 hours later. The dose can then be repeated twice per day for 1 to 2 days following chemotherapy (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 928-930).
- The oral bioavailability of ondansetron is about 60 percent with effective blood levels appearing 30 to 60 minutes after administration. Ondansetron is extensively metabolized by the liver with a plasma half-life of about 3 to 4 hours. Adverse effects of ondansetron are mild and include headaches, constipation, and dizziness (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 928-930).
- A buccal aerosol spray or soft bite gelatin capsule using a polar or non-polar solvent has now been developed which provides biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect.
- The buccal aerosol spray compositions of the present invention, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable non-polar solvent comprise in weight % of total composition: pharmaceutically acceptable propellant 5-80%, nonpolar solvent 19-85%, active compound 0.05-50%, suitably additionally comprising, by weight of total composition a flavoring agent 0.01-10%. Preferably the composition comprises: propellant 10-70%, non-polar solvent 25-89.9%, active compound 0.01-40%, flavoring agent 1-8%; most suitably propellant 20-70%, non-polar solvent 25-74.75%, active compound 0.25-35%, flavoring agent 2-7.5%.
- The buccal polar aerosol spray compositions of the present invention, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent are also administrable in aerosol form driven by a propellant. In this case, the composition comprises in weight % of total composition: aqueous polar solvent 10-97%, active compound 0.1-25%, suitably additionally comprising, by weight of total composition a flavoring agent 0.05-10% and propellant: 2-10%. Preferably the composition comprises: polar solvent 20-97%, active compound 0.1-15%, flavoring agent 0.1-5% and propellant 2-5%; most suitably polar solvent 25-97%, active compound 0.2-25%, flavoring agent 0.1-2.5% and propellant 2-4%.
- In another embodiment, the buccal polar aerosol spray compositions of the present invention for transmucosal administration of a pharmacologically active compound (i.e., those administrable in aerosol form driven by a propellant) comprises a mixture of a polar solvent and a non-polar solvent comprising in weight % of total composition: solvent 10-97%, active compound 0.05-50%, propellant 5-80%, and optionally a taste mask and/or flavoring agent 0.01-10%. Preferably the composition comprises: solvent 20-97%, active compound 0.1-40%, propellant 10-70%, and taste mask and/or flavoring agent 1-8%; most suitably solvent 25-97%, active compound 0.25-35%, propellant 20-70%, and taste mask and/or flavoring agent 2-7.5%. The ratio of the polar solvent to the non-polar solvent can range from about 1:99 to about 99:1, preferable from about 60:40 to about 40:60, and more preferably about 50:50.
- The buccal pump spray composition of the present invention, i.e., the propellant free composition, for transmucosal administration of a pharmacologically active compound wherein said active compound is soluble in a pharmacologically acceptable non-polar solvent comprises in weight % of total composition: non-polar solvent 30-99.69%, active compound 0.005-55%, and suitably additionally, flavoring agent 0.1-10%.
- The buccal polar pump spray compositions of the present invention, i.e., the propellant free composition, for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent comprises in weight % of total composition: aqueous polar solvent 30-99.69%, active compound 0.001-60%, suitably additionally comprising, by weight of total composition a flavoring agent 0.1-10%. Preferably the composition comprises: polar solvent 37-98.58%, active compound 0.005-55%, flavoring agent 0.5-8%; most suitably polar solvent 60.9-97.06%, active compound 0.01-40%, flavoring agent 0.75-7.5%.
- In another embodiment, the buccal pump spray composition (i.e., the propellant free composition) for transmucosal administration of a pharmacologically active compound comprises a mixture of a polar solvent and a non-polar solvent comprising in weight % of total composition solvent 30-99.69%, active compound 0.001-60%, and optionally a taste mask and/or flavoring agent 0.1-10%. Preferably the composition comprises: solvent 37-98.58%, active compound 0.005-55%, taste mask and/or flavoring agent 0.5-8%; more preferably the composition comprises solvent 60.9-97.06%, active compound 0.01-40%, and taste mask and/or flavoring agent 0.75-7.5%. The ratio of the polar solvent to the non-polar solvent can range from about 1:99 to about 99:1, preferable about 60:40 to about 40:60, and more preferably about 50:50.
- The soft bite gelatin capsules of the present invention for transmucosal administration of a pharmacologically active compound, at least partially soluble in a pharmacologically acceptable non-polar solvent, having charged thereto a fill composition comprise in weight % of total composition: non-polar solvent 4-99.99%, emulsifier 0-20%, active compound 0.01-80%, provided that said fill composition contains less than 10% of water, suitably additionally comprising, by weight of the composition: flavoring agent 0.01-10%. Preferably, the soft bite gelatin capsule comprises: non-polar solvent 21.5-99.975%, emulsifier 0-15%, active compound 0.025-70%, flavoring agent 1-8%; most suitably: nonpolar solvent 28.5-97.9%, emulsifier 0-10%, active compound 0.1-65.0%, flavoring agent 2-6%.
- The soft bite polar gelatin capsules of the present invention for transmucosal administration of a pharmacologically active compound, at least partially soluble in a pharmacologically acceptable polar solvent, having charged thereto a composition comprising in weight % of total composition: polar solvent 25-99.89%, emulsifier 0-20%, active compound 0.01-65%, provided that said composition contains less than 10% of water, suitably additionally comprising, by weight of the composition: flavoring agent 01-10%. Preferably, the soft bite gelatin capsule comprises: polar solvent 37-99.95%, emulsifier 0-15%, active compound 0.025-55%, flavoring agent 1-8%; most suitably: polar solvent 44-96.925%, emulsifier 0-10%, active compound 0.075-50%, flavoring agent 2-6%.
- It is an object of the invention to coat the mucosal membranes either with extremely fine droplets of spray containing the active compounds or a solution or paste thereof from bite capsules.
- It is also an object of the invention to administer to the oral mucosa of a mammalian in need of same, preferably man, by spray or bite capsule, a predetermined amount of a biologically active compound by this method or from a soft gelatin capsule.
- A further object is a sealed aerosol spray container containing a composition of the non polar or polar aerosol spray formulation, and a metered valve suitable for releasing from said container a predetermined amount of said composition.
- As the propellant evaporates after activation of the aerosol valve, a mist of fine droplets is formed which contains solvent and active compound.
- The propellant is a non-Freon material, preferably a C3-8 hydrocarbon of a linear or branched configuration. The propellant should be substantially non-aqueous. The propellant produces a pressure in the aerosol container such that under expected normal usage it will produce sufficient pressure to expel the solvent from the container when the valve is activated but not excessive pressure such as to damage the container or valve seals.
- The non-polar solvent is a non-polar hydrocarbon, preferably a C7-18 hydrocarbon of a linear or branched configuration, fatty acid esters, and triglycerides, such as miglyol. The solvent must dissolve the active compound and be miscible with the propellant, i.e., solvent and propellant must form a single phase at a temperature of 0-40° C. a pressure range of between 1-3 atm.
- The polar and non-polar aerosol spray compositions of the invention are intended to be administered from a sealed, pressurized container. Unlike a pump spray, which allows the entry of air into the container after every activation, the aerosol container of the invention is sealed at the time of manufacture. The contents of the container are released by activation of a metered valve, which does not allow entry of atmospheric gasses with each activation. Such containers are commercially available.
- A further object is a pump spray container containing a composition of the pump spray formulation, and a metered valve suitable for releasing from said container a predetermined amount of said composition.
- A further object is a soft gelatin bite capsule containing a composition of as set forth above. The formulation may be in the form of a viscous solution or paste containing the active compounds. Although solutions are preferred, paste fills may also be used where the active compound is not soluble or only partially soluble in the solvent of choice. Where water is used to form part of the paste composition, it should not exceed 10% thereof. (All percentages herein are by weight unless otherwise indicated.)
- The polar or non-polar solvent is chosen such that it is compatible with the gelatin shell and the active compound. The solvent preferably dissolves the active compound. However, other components wherein the active compound is not soluble or only slightly soluble may be used and will form a paste fill.
- Soft gelatin capsules are well known in the art. See, for example, U.S. Pat. No. 4,935,243, Borkan et al., for its teaching of such capsules. The capsules of the present invention are intended to be bitten into to release the low viscosity solution or paste therein, which will then coat the buccal mucosa with the active compounds. Typical capsules, which are swallowed whole or bitten and then swallowed, deliver the active compounds to the stomach, which results in significant lag time before maximum blood levels can be achieved or subject the compound to a large first pass effect. Because of the enhanced absorption of the compounds through the oral mucosa and no chance of a first pass effect, use of the bite capsules of the invention will eliminate much of the lag time, resulting in hastened onset of biological effect. The shell of a soft gelatin capsule of the invention may comprise, for example: gelatin: 50-75%, glycerin 20-30%, colorants 0.5-1.5%, water 5-10%, and sorbitol 2-10%.
- The active compound may include, biologically active peptides, central nervous system active amines, sulfonyl ureas, antibiotics, antifungals, antivirals, sleep inducers, antiasthmatics, bronchial dilators, antiemetics, histamine H-2 receptor antagonists, barbiturates, prostaglandins and neutraceuticals.
- The active compounds may also include antihistamines, alkaloids, hormones, benzodiazepines and narcotic analgesics. While not limited thereto, these active compounds are particularly suitable for non-polar pump spray formulation and application.
- The active compounds may also include anti-diuretics, anti-muscle spasm agents, anti-spasmodics, agents for treating urinary incontinence, anti-diarrheal agents, agents for treating nausea and/or vomiting, smooth muscle contractile agents, anti-secretory agents, enzymes, anti-diuretics, anti-ulcerants, bile acid replacement and/or gallstone solubilizing drugs, or mixtures thereof.
- In one embodiment, the active compound is ondansetron or a pharmaceutically acceptable salt thereof.
-
FIG. 1 . is a schematic diagram showing routes of absorption and processing of pharmacologically active substances in a mammalian system. - The preferred active compounds of the present invention are in an ionized, salt form or as the free base of the pharmaceutically acceptable salts thereof (provided, for the aerosol or pump spray compositions, they are soluble in the spray solvent). These compounds are soluble in the non-polar solvents of the invention at useful concentrations or can be prepared as pastes at useful concentrations. These concentrations may be less than the standard accepted dose for these compounds since there is enhanced absorption of the compounds through the oral mucosa. This aspect of the invention is especially important when there is a large (40-99.99%) first pass effect.
- As propellants for the non polar sprays, propane, N-butane, iso-butane, N-pentane, iso-pentane, and neo-pentane, and mixtures thereof may be used. N-butane and iso-butane, as single gases, are the preferred propellants. It is permissible for the propellant to have a water content of no more than 0.2%, typically 0.1-0.2%. All percentages herein are by weight unless otherwise indicated. It is also preferable that the propellant be synthetically produced to minimize the presence of contaminants which are harmful to the active compounds. These contaminants include oxidizing agents, reducing agents, Lewis acids or bases, and water. The concentration of each of these should be less than 0.1%, except that water may be as high as 0.2%.
- Suitable non-polar solvents for the capsules and the non-polar sprays include (C2-C24) fatty acid (C2-C6) esters, C7-C18 hydrocarbon, C2-C6 alkanoyl esters, and the triglycerides of the corresponding acids. When the capsule fill is a paste, other liquid components may be used instead of the above low molecular weight solvents. These include soya oil, corn oil, other vegetable oils.
- As solvents for the polar capsules or sprays there may be used low molecular weight polyethyleneglycols (PEG) of 400-1000 Mw (preferably 400-600), low molecular weight (C2-C8) mono and polyols and alcohols of C7-C18 linear or branch chain hydrocarbons, glycerin may also be present and water may also be used in the sprays, but only in limited amount in the capsules.
- It is expected that some glycerin and water used to make the gelatin shell will migrate from the shell to the fill during the curing of the shell. Likewise, there may be some migration of components from the fill to the shell during curing and even throughout the shelf-life of the capsule.
- Therefore, the values given herein are for the compositions as prepared, it being within the scope of the invention that minor variations will occur.
- The preferred flavoring agents are synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners (sugars, aspartame, saccharin, etc.), and combinations thereof.
- The compositions may further include a taste mask. The term “taste mask” as used herein means an agent that can hide or minimize an undesirable flavor such as a bitter or sour flavor. A representative taste mask is a combination of vanillin, ethyl vanillin, maltol, iso-amyl acetate, ethyl oxyhydrate, anisic aldehyde, and propylene glycol (commercially available as “PFC 9885 Bitter Mask” from Pharmaceutical Flavor Clinic of Camden, N.J.). A taste mask in combination with a flavoring agent is particularly advantageous when the active compound is an alkaloid since alkaloids often have a bitter taste.
- The active substances include the active compounds selected from the group consisting of cyclosporine, sermorelin, octreotide acetate, calcitonin-salmon, insulin lispro, sumatriptan succinate, clozepine, cyclobenzaprine, dexfenfluramine hydrochloride, glyburide, zidovudine, erythromycin, ciprofloxacin, ondansetron hydrochloride, dimenhydrinate, cimetidine hydrochloride, famotidine, phenyloin sodium, phenyloin, carboprost thromethamine, carboprost, diphenhydramine hydrochloride, isoproterenol hydrochloride, terbutaline sulfate, terbutaline, theophylline, albuterol sulfate and neutraceuticals, that is to say nutrients with pharmacological action such as but not limited to carnitine, valerian, echinacea, and the like.
- In another embodiment, the active compound is an anti-diuretic, anti-muscle spasm agent, anti-spasmodic, agent for treating urinary incontinence, anti-diarrheal agent, agent for treating nausea and/or vomiting, smooth muscle contractile agent, anti-secretory agent, enzyme, anti-diuretic, anti-ulcerant, bile acid replacement and/or gallstone solubilizing drug, or a mixture thereof.
- In one embodiment the active compound is an anti-diuretic. Suitable anti-diuretics for use in the buccal sprays of the invention include, but are not limited to, acetazolamide, benzthiazide, bendroflumethazide, bumetamide, chlorthalidone, chlorothiazide, ethacrynic acid, furosemide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, quinethazone, spironolactone, triamterene, torsemide, trichlomethiazide, and mixtures thereof.
- In one embodiment the active compound is an anti-muscle spasm agent. Suitable anti-muscle spasm agents for use in the buccal sprays of the invention include, but are not limited to, baclofen, botulinum toxin, carisoprodol, chlorphenesin, chlorzoxazone, cyclobenzaprine, dantrolene, diazepam, metaxalone, methocarbamol, orphenadrine, tizanidine, and mixtures thereof.
- In one embodiment the active compound is an anti-spasmodic. Suitable anti-spasmodics for use in the buccal sprays of the invention include, but are not limited to, atropine, baclofen, dicyclomine, hyoscine, propatheline, oxybutynin, S-oxybutynin, tizanidine, and mixtures thereof.
- In one embodiment the active compound is an agent for treating urinary incontinence. Suitable agents for treating urinary incontinence for use in the buccal sprays of the invention include, but are not limited to, darifenacin, vamicamide, detrol, ditropan, imipramine, and mixtures thereof.
- In one embodiment the active compound is an anti-diarrheal agent. Suitable anti-diarrheal agents for use in the buccal sprays of the invention include, but are not limited to, ondansetron, palnosetron, tropisetron, attapulgite, atropine, bismuth, diphenoxylate, loperamide, and mixtures thereof.
- In one embodiment the active compound is an agent for treating nausea and/or vomiting. Suitable agents for treating nausea and/or vomiting for use in the buccal sprays of the invention include, but are not limited to, alosetron, dolasetron, granisetron, meclizine, metoclopramide, ondansetron, palnosetron, prochloperazine, promethazine, trimethobenzamiode, tropisetron, and mixtures thereof.
- In one embodiment the active compound is a smooth muscle contractile agent. A suitable smooth muscle contractile agents for use in the buccal sprays of the invention includes, but is not limited to hyoscine.
- In one embodiment the active compound is an anti-secretory agent. Suitable anti-secretory agents for use in the buccal sprays of the invention include, but are not limited to, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, tenetoprazole, ecabet, misoprostol, teprenone, and mixtures thereof.
- In one embodiment the active compound is an enzyme. Suitable enzymes for use in the buccal sprays of the invention include, but are not limited to, alpha-galactosidase, alpha-L-iduronidase, imiglucerase/alglucerase, anylase, lipase, protease, pancreatin, olsalazine, and mixtures thereof.
- In one embodiment the active compound is an anti-diuretic. Suitable anti-diuretics for use in the buccal sprays of the invention include, but are not limited to, desmopressin, oxytocin, and mixtures thereof.
- In one embodiment the active compound is an anti-ulcerant. Suitable anti-ulcerants for use in the buccal sprays of the invention include, but are not limited to, cimetidine, ranitidine, famotidine, misoprostol, sucralfate, pantoprazole, lansoprazole, omeprazole, and mixtures thereof.
- In one embodiment the active compound is a bile acid replacement and/or gallstone solubilizing drug. A suitable bile acid replacement and/or gallstone solubilizing drug for use in the buccal sprays of the invention includes, but is not limited to ursodiol.
- In one embodiment, the active compound is ondansetron, or a pharmaceutically acceptable salt thereof. In one embodiment, the active compound is ondansetron hydrochloride.
- Typically, when ondansetron, or a pharmaceutically acceptable salt thereof, is the active compound the buccal spray contains from about contains form about 0.01 to 20 weight/weight (w/w) percent ondansetron, or a pharmaceutically acceptable salt thereof, preferably, about 0.1 to 15 w/w percent, and more preferably about 0.2 to 10 w/w percent ondansetron, or a pharmaceutically acceptable salt thereof.
- The invention further relates to a method for treating emesis in a patient by spraying the oral mucosa of the patient with a therapeutically effective amount of a buccal spray comprising ondansetron or a pharmaceutically acceptable salt thereof.
- In one embodiment, the emesis is chemotherapy induced emesis.
- In another embodiment, the emesis is radiation induced emesis.
- In another embodiment, the ondansetron, or a pharmaceutically acceptable salt thereof, is administered in combination with a corticosteroid, such as phenothiazine or butyrophenone.
- In another embodiment, the ondansetron, or a pharmaceutically acceptable salt thereof, is administered in combination with dexamethasone.
- In another embodiment for treating chemotherapy or radiation induced emesis, the oral mucosa of the patient is sprayed with ondansetron, or a pharmaceutically acceptable salt thereof, before chemotherapy or radiation therapy begins. Typically, ondansetron, or a pharmaceutically acceptable salt thereof, is sprayed on the oral mucosa of the patient between about 5 minutes and about 2 hours before chemotherapy or radiation therapy begins, preferably between about 15 minutes and about 1 hour, more preferably between about 30 minutes before chemotherapy or radiation therapy begins. In another embodiment, the method further includes administering ondansetron, or a pharmaceutically acceptable salt thereof, after chemotherapy or radiation therapy is ended. Typically, the ondansetron, or a pharmaceutically acceptable salt thereof, is sprayed on the oral mucosa of the patient between about 1 hour and 6 hours after chemotherapy or radiation therapy has ended, preferable between about 2 hours and about 5 hours, more preferably about 4 hours after chemotherapy or radiation therapy has ended.
- In another embodiment, the emesis is anesthetic induced emesis. Accordingly, the invention further relates to a method of administering anesthesia by spraying the oral mucosa of the patient with a therapeutically effective amount of a buccal spray comprising ondansetron or a pharmaceutically acceptable salt thereof before the anesthesis is administered.
- The invention further relates to a method for treating anxiety in a patient by spraying the oral mucosa of the patient with a therapeutically effective amount of a buccal spray comprising ondansetron or a pharmaceutically acceptable salt thereof.
- The formulations of the present invention comprise an active compound or a pharmaceutically acceptable salt thereof. The term “pharmaceutically acceptable salts”refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including organic and inorganic acids or bases.
- When an active compound of the present invention is acidic, salts may be prepared from pharmaceutically acceptable non-toxic bases. Salts derived from all stable forms of inorganic bases include aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, zinc, etc. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins such as arginine, betaine, caffeine, choline, N,N dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethyl-aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methyl-glucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, etc.
- When an active compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethane-sulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, etc. Particularly preferred are citric, hydrobromic, maleic, phosphoric, sulfuric, and tartaric acids.
- In the discussion of methods of treatment herein, reference to the active compounds is meant to also include the pharmaceutically acceptable salts thereof. While certain formulations are set forth herein, the actual amounts to be administered to the mammal or man in need of same are to be determined by the treating physician.
- The invention is further defined by reference to the following examples, which are intended to be illustrative and not limiting.
- The following are examples of certain classes. All values unless otherwise specified are in weight percent.
- A. Cyclosporine Lingual Spray
preferred most preferred Amounts amount amount cyclosporine 5-50 10-35 15-25 water 5-20 7.5-50 9.5-12 ethanol 5-60 7.5-50 10-20 polyethylene glycol 20-60 30-45 35-40 flavors 0.1-5 1-4 2-3 - B. Cyclosporine Non-Polar Lingual Spray
preferred most preferred Amounts amount amount cyclosporine 1-50 3-40 5-30 Migylol 20 25 30-40 Polyoxyethylated castor oil 20 25 30-40 Butane 25-80 30-70 33-50 flavors 0.1-5 1-4 2-3 - C. Cyclosporine Non-Polar Bite Caosule
preferred most preferred Amounts amount amount cyclosporine 1-35 5-25 10-20 olive oil 25-60 35-55 30-45 polyoxyethylated 25-60 35-55 30-45 oleic glycerides flavors 0.1-5 1-4 2-3 - D. Cyclosporine Bite Capsule
preferred most preferred Amounts amount amount cyclosporine 5-50 10-35 15-25 polyethylene 20-60 30-45 35-40 glycol glycerin 5-30 7.5-25 10-20 propylene glycol 5-30 7.5-25 10-20 flavors 0.1-10 1-8 3-6 - E. Sermorelin (as the Acetate) Lingual Spray
preferred most Amounts amount preferred sermorelin (as the acetate) .01-5 .1-3 .2-1.0 mannitol 1-25 5-20 10-15 monobasic sodium phosphate, 0.1-5 1-31 .5-2.5 dibasic sodium phosphate water 0.01-5 .05-3 0.1-0.5 ethanol 5-30 7.5-25 9.5-15 polyethylene glycol 20-60 30-45 35-40 propylene glycol 5-25 10-20 12-17 flavors 0.1-5 1-4 2-3 - F. Octreotide Acetate (Sandostatin) Lingual Spray
preferred most preferred Amounts amount amount octreotide acetate 0.001-0.5 0.005-0.250 0.01-0.10 acetic acid 1-10 2-8 4-6 sodium acetate 1-10 2-8 4-6 sodium chloride 3-30 .5-25 15-20 flavors 0.1-5 0.5-.4 2-3 ethanol 5-30 7.5-20 9.5-15 water 15-95 35-90 65-85 flavors 0.1-5 1-4 2-3 - G. Calcitonin-Salmon Lingual Spray
preferred most preferred Amounts amount amount calcitonin-salmon 0.001-5 0.005-2 01-1.5 ethanol 2-15 3-10 7-9.5 water 30-95 50-90 60-80 polyethylene 2-15 3-10 7-9.5 glycol sodium chloride 2.5-20 5-15 10-12.5 flavors 0.1-5 1-4 2-3 - H. Insulin Lispro, Lingual Spray
preferred most preferred Amounts amount amount insulin 20-60 4-55 5-50 glycerin 0.1-10 0.25-5 0.1-1.5 dibasic sodium 1-15 2.5-10 4-8 phosphate m-cresol, 1-25 5-25 7.5-12.5 zinc oxide 0.01-0.25 .05-0.15 0.075-0.10 m-cresol 0.1-1 0.2-0.8 0.4-0.6 phenol trace amounts trace amounts trace amounts ethanol 5-20 7.5-15 9-12 water 30-90 40-80 50-75 propylene glycol 5-20 7.5-15 9-12 flavors 0.1-5 0.5-3 0.75-2 adjust pH to 7.0-7.8 with HCl or NaOH - CNS Active Amines and Their Salts: Including but not Limited to Tricyclic Amines, GABA Analogues, Thiazides, Phenothiazine Derivatives, Serotonin Antagonists and Serotonin Reuptake Inhibitors
- A. Sumatriptan Succinate Lingual Spray
preferred most preferred Amounts amount amount sumatriptan succinate 0.5-30 1-20 10-15 ethanol 5-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 5-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3 - B. Sumatriptan Succinate Bite Capsule
preferred most preferred Amounts amount amount sumatriptan succinate 0.01-5 0.05-3.5 0.075-1.75 polyethylene glycol 25-70 30-60 35-50 glycerin 25-70 30-60 35-50 flavors 0.1-10 1-8 3-6 - C. Clozepine Lingual Spray
preferred most preferred Amounts amount amount clozepine 0.5-30 1-20 10-15 ethanol 5-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 5-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3 - D. Clozepine Non-Polar Lingual Spray with Propellant
preferred most preferred Amounts amount amount clozepine 0.5-30 1-20 10-15 Migylol 20-85 25-70 30-40 Butanol 5-80 30-75 60-70 flavors 0.1-5 1-4 2-3 - E. Clozepine Non-Polar Lingual Spray Without Propellant
preferred most preferred Amounts amount amount clozepine 0.5-30 1-20 10-15 Migylol 70-99.5 80-99 85-90 flavors 0.1-5 1-4 2-3 - F. Cyclobenzaprine Non-Polar Lingual Spray
preferred most preferred Amounts amount amount cyclobenzaprine (base) 0.5-30 1-20 10-15 Migylol 20-85 25-70 30-40 Iso-butane 15-80 30-75 60-70 flavors 0.1-5 1-4 2-3 - G. Dexfenfluramine Hydrochloride Lingual Spray
preferred most preferred Amounts amount amount dexfenfluramine Hcl 5-30 7.5-20 10-15 ethanol 5-60 7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 5-30 7.5-20 10-15 flavors 0.1-5 1-4 2-3 - A. Glyburide Lingual Spray
preferred most preferred Amounts amount amount glyburide 0.25-25 0.5-20 0.75-15 ethanol 5-60 −7.5-50 10-20 propylene glycol 5-30 7.5-20 10-15 polyethylene glycol 0-60 30-45 35-40 water 2.5-30 5-20 6-15 flavors 0.1-5 1-4 2-3 - B. Glyburide Non-Polar Bite Capsule
preferred most preferred Amounts amount amount glyburide 0.01-10 0.025-7.5 0.1-4 olive oil 30-60 35-55 30-50 polyoxyethylated oleic 30-60 35-55 30-50 glycerides flavors 0.1-5 1-4 2-3 - A. Zidovudine [Formerly Called Azidothymidine (AZT) (Retrovir)] Non-Polar Lingual Spray
preferred most preferred Amounts amount amount zidovudine 10-50 15-40 25-35 Soya oil 20-85 25-70 30-40 Butane 15-80 30-75 60-70 flavors 0.1-5 1-4 2-3 - B. Erythromycin Bite Capsule Bite Capsule
preferred most preferred Amounts amount amount erythromycin 25-65 30-50 35-45 polyoxyethylene 5-70 30-60 45-55 glycol glycerin 5-20 7.5-15 10-12.5 flavors 1-10 2-8 3-6 - C. Ciprofloxacin Hydrochloride Bite Capsule
preferred most preferred Amounts amount amount ciprofloxacin hydrochloride 25-65 35-55 40-50 glycerin 5-20 7.5-15 10-12.5 polyethylene glycol 120-75 30-65 40-60 flavors 1-10 2-8 3-6 - D. Zidovudine [Formerly Called Azidothymidine (AZT) (Retrovir)] Lingual Spray
preferred most preferred Amounts amount amount zidovudine 10-50 15-40 25-35 water 30-80 40-75 45-70 ethanol 5-20 7.5-15 9.5-12.5 polyethylene glycol 5-20 7.5-15 9.5-12.5 flavors 0.1-5 1-4 2-3 - Anti-Emetics
- A. Ondansetron Hydrochloride Lingual Spray
preferred most preferred Amounts amount amount ondansetron hydrochloride 1-25 2-20 2.5-15 citric acid monohydrate 1-10 2-8 2.5-5 sodium citrate dihydrate 0.5-5 1-4 1.25-2.5 water 1-90 5-85 10-75 ethanol 5-30 7.5-20 9.5-15 propylene glycol 5-30 7.5-20 9.5-15 polyethylene glycol 5-30 7.5-20 9.5-15 flavors 1-10 3-8 5-7.5 - B. A Propellant Free Ondansetron Formulation in a Polar Solvent can be made According to the Following Formula:
Component Percent (w/w) Ondansetron Hydrochloride 4 Tween 80 0.5 EDTA 0.02 Ethanol 10 Glycerol 5 Water QS to 100 - C. A propellant Free Ondansetron Formulation in a Non-Polar Solvent can be made According to the Following Formula
Component Percent (w/w) Ondansetron 0.2 Bitter Mask 0.50.1 Alpha-tocopherol Acetate 2 Liquid Paraffin QS to 100 - D. A Propellant Free Ondansetron Formulation in a Mixture of a Polar Solvent and a Non-Polar Solvent can be made According to the Following Formula
Component Percent (w/w) Ondansetron 0.1 Miglyol 810 20 Polysorbate (span) 1 Lemon Oil 0.1 Ethanol QS to 100 - E. An Ondansetron Formulation in a Non-Polar Solvent with a Propellant can be made According to the Following Formula:
Component Percent (w/w) Ondansetron 0.1 Lemon Oil 0.2 Miglyol 20 Butane 100 - F. An Ondansetron Formulation in a Polar Solvent with a Propellant can be made According to the Following Formula:
Component Percent (w/w) Ondansetron 2 Bitter mask 0.2 Ethanol 60 Butane 100 - G. An Ondansetron Formulation in a Mixture of a Polar Solvent and a Non-Polar Solvent with a Propellant can be made According to the Following Formula:
Component Percent (w/w) Ondansetron 0.1 Miglyol 20 Polysorbate (span) 1 Lemon Oil 0.1 Ethanol 20 Butane 100 - H. Dimenhydrinate Bite Capsule
preferred most preferred Amounts amount amount dimenhydrinate 0.5-30 2-25 3-15 glycerin 5-20 7.5-15 10-12.5 polyethylene glycol 45-95 50-90 55-85 flavors 1-10 2-8 3-6 - I. Dimenhydrinate Polar Lingual Spray
preferred most preferred Amounts amount amount dimenhydrinate 3-50 4-40 5-35 water 5-90 10-80 15-75 ethanol 1-80 3-50 5-10 polyethylene glycol 1-80 3-50 5-15 sorbitol 0.1-5 0.2-40 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 - Histamine H-2 Receptor Antagonists
- A. Cimetidine Hydrochloride Bite Capsule
preferred most preferred Amounts amount amount cimetidine HCl 10-60 15-55 25-50 glycerin 5-20 7.5-15 10-12.5 polyethylene glycol 20-90 25-85 30-75 flavors 1-10 2-8 3-6 - B. Famotidine Lingual Spray
preferred most preferred Amounts amount amount famotidine 1-35 5-30 7-20 water 2.5-25 3-20 5-10 L-aspartic acid 0.1-20 1-15 5-10 polyethylene glycol 20-97 30-95 50-85 flavors 0.1-10 1-7.5 2-5 - C. Famotidine Non-Polar Lingual Spray
preferred most preferred Amounts amount amount famotidine 1-35 5-30 7-20 Soya oil 10-50 15-40 15-20 Butane1 5-80 30-75 45-70 polyoxyethylated 10-50 15-40 15-20 oleic glycerides flavors 0.1-5 1-4 2-3 - A. Phenytoin Sodium Lingual Spray
preferred most preferred Amounts amount amount phenytoin sodium 10-60 15-55 20-40 water 2.5-25 3-20 5-10 ethanol 5-30 7.5-20 9.5-15 propylene glycol 5-30 7.5-20 9.5-15 polyethylene glycol 5-30 7.5-20 9.5-15 flavors 1-10 3-8 5-7.5 - B. Phenytoin Non-Polar Lingual Spray
preferred most preferred Amounts amount amount phenytoin 5-45 10-40 15-35 migylol 10-50 15-40 15-20 Butane 15-80 30-75 60-70 polyoxyethylated 10-50 15-40 15-20 oleic glycerides flavors 0.1-10 1-8 5-7.5 - A. Carboprost Thromethamine Lingual Spray
preferred most preferred Amounts amount amount carboprost thromethamine 0.05-5 0.1-3 0.25-2.5 water 50-95 60-80 65-75 ethanol 5-20 7.5-15 9.5-12.5 polyethylene glycol 5-20 7.5-15 9.5-12.5 sodium chloride 1-20 3-15 4-8 flavors 0.1-5 1-4 2-3
pH is adjusted with sodium hydroxide and/or hydrochloric acid - B. Carboprost Non-Polar Lingual Spray
preferred most preferred Amounts amount amount carboprost 0.05-5 0.1-3 0.25-2.5 migylol 25-50 30-45 35-40 Butane 5-60 10-50 20-35 polyoxyethylated 25-50 30-45 35-40 oleic glycerides flavors 0.1-10 1-8 5-7.5 - A. Carnitine as Bite Capsule (Contents are a Paste)
preferred most preferred Amounts amount amount carnitine fumarate 6-80 30-70 45-65 soya oil 7.5-50 10-40 12.5-35 soya lecithin 0.001-1.0 0.005-0.5 .01-0.1 Soya fats 7.5-50 10-40 12.5-35 flavors 1-10 2-8 3-6 - B. Valerian as Lingual Spray
preferred most preferred Amounts amount amount valerian extract 0.1-10 0.2-7 0.25-5 water 50-95 60-80 65-75 ethanol 5-20 7.5-15 9.5-12.5 polyethylene glycol 5-20 7.5-15 9.5-12.5 flavors 1-10 2-8 3-6 - C. Echinacea as Bite Capsule
preferred most preferred Amounts amount amount echinacea extract 30-85 40-75 45-55 soya oil 7.5-50 10-40 12.5-35 soya lecithin 0.001-1.0 0.005-0.5 .01-0.1 Soya fats 7.5-50 10-40 12.5-35 flavors 1-10 2-8 3-6 - D. Mixtures of Ingredients
preferred most preferred Amounts amount amount magnesium oxide 15-40 20-35 25-30 chromium picolinate 0.01-1.0 0.02-0.5 .025-0.75 folic acid .025-3.0 0.05-2.0 0.25-0.5 vitamin B-12 0.01-1.0 0.02-0.5 .025-0.75 vitamin E 15-40 20-35 25-30 Soya oil 10-40 12.5-35 15-20 soya lecithin 0.1-5 0.2-4 0.5-1.5 soya fat 10-40 15-35 17.5-20 - A. Diphenhydramine Hydrochloride Lingual Spray
preferred most preferred Amounts amount amount diphenhydramine 3-50 4-40 5-35 HCl water 5-90 10-80 50-75 ethanol 1-80 3-50 5-10 polyethylene glycol 1-80 3-50 5-15 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 - A. Isoproterenol Hydrochloride as Polar Lingual Spray
preferred most preferred Amounts amount amount isoproterenol Hydrochloride 0.1-10 0.2-7.5 0.5-6 water 5-90 10-80 50-75 ethanol 1-80 3-50 5-10 polyethylene glycol 1-80 3-50 5-15 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 -
preferred most preferred Amounts amount amount terbutaline sulfate 0.1-10 0.2-7.5 0.5-6 water 5-90 10-80 50-75 ethanol 1-10 2-8 2.5-5 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 -
preferred most preferred Amounts amount amount terbutaline 0.1-10 0.2-7.5 0.5-6 migylol 25-50 30-45 35-40 isobutane 5-60 10-50 20-35 polyoxyethylated 25-50 30-45 35-40 oleic glycerides flavors 0.1-10 1-8 5-7.5 - D. Theophylline Polar Bite Capsule
preferred most preferred Amounts amount amount theophylline 5-50 10-40 15-30 polyethylene glycol 20-60 25-50 30-40 glycerin 25-50 35-45 30-40 propylene glycol 25-50 35-45 30-40 flavors 0.1-5 1-4 2-3 - E. Albuterol Sulfate as Polar Lingual Spray
preferred most preferred Amounts amount amount albuterol sulfate 0.1-10 0.2-7.5 0.5-6 water 5-90 10-80 50-75 ethanol 1-10 2-8 2.5-5 Sorbitol 0.1-5 0.2-4 0.4-1.0 aspartame 0.01-0.5 0.02-0.4 0.04-0.1 flavors 0.1-5 1-4 2-3 - Polar Solvent Formulations Using a Propellant:
- A. Sulfonylurea
Preferred Most-preferred Amount Amount amount glyburide 0.1-25% 0.5-15% 0.6-10% Ethanol 40-99% 60-97% 70-97% Water 0.01-5% 0.1-4% 0.2-2% Flavors 0.05-10% 0.1-5% 0.1-2.5% Propellant 2-10% 3-5% 3-4% - B. Prostaglandin E (vasodilator)
preferred Most-preferred Amount amount amount prostaglandin E1 0.01-10% 0.1-5% 0.2-3% Ethanol 10-90% 20-75% 25-50% Propylene glycol 1-90% 5-80% 10-75% Water 0.01-5% 0.1-4% 0.2-2% Flavors 0.05-10% 0.1-5% 0.1-2.5% Propellant 2-10% 3-5% 3-4% - C. Promethazine (Antiemetic, Sleep Inducer, and CNS Active Amine)
preferred Most-preferred Amount amount amount promethazine 1-25% 3-15% 5-12% Ethanol 10-90% 20-75% 25-50% Propylene glycol 1-90% 5-80% 10-75% Water 0.01-5% 0.1-4% 0.2-2% Flavors 0.05-10% 0.1-5% 0.1-2.5% Propellant 2-10% 3-5% 3-4% - D. Meclizine
Preferred Most-Preferred Amount Amount Amount meclizine 1-25% 3-15% 5-12% Ethanol 1-15% 2-10% 3-6 Propylene glycol 20-98% 5-90% 10-85% Water 0.01-5% 0.1-4% 0.2-2% Flavors 0.05-10% 0.1-5% 0.1-2.5% Propellant 2-10% 3-5% 3-4%
Claims (60)
1-10. (canceled)
11. An oral spray composition for transmucosal administration of ondansetron or a pharmaceutically acceptable salt thereof comprising: ondansetron or a pharmaceutically acceptable salt thereof in an amount of between 0.1 and 25 percent by weight of the total composition; a polar solvent in an amount between 10 and 97 percent by weight of the total composition; and a propellant in an amount between 2 and 10 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or branched configuration.
12. The composition of claim 11 , further comprising a taste mask and/or flavoring agent in an amount between 0.05 and 10 percent by weight of the total composition.
13. The composition of claim 12 , wherein the polar solvent is present in an amount between 20 and 97 percent by weight of the total composition, the ondansetron or a pharmaceutically acceptable salt thereof is present in an amount between 0.1 and 15 percent by weight of the total composition, the propellant is present in an amount between 2 and 5 percent by weight of the composition, and the taste mask and/or flavoring agent is present in an amount between 0.1 and 5 percent by weight of the total composition.
14. The composition of claim 13 , wherein the polar solvent is present in an amount between 25 and 97 percent by weight of the total composition, the ondansetron or a pharmaceutically acceptable salt thereof is present in an amount between 0.2 and 25 percent by weight of the total composition, the propellant is present in an amount between 2 and 4 percent by weight of the composition, and taste mask and/or flavoring agent is present in an amount between 0.1 and 2.5 percent by weight of the total composition.
15. The composition of claim 11 , wherein the polar solvent is selected from the group consisting of polyethyleneglycols having a molecular weight between 400 and 1000, C2 to C8 mono- and poly-alcohols, and C7 to C18 alcohols of linear or branched configuration.
16. The composition of claim 15 , wherein the polar solvent comprises polyethylene glycol.
17. The composition of claim 15 , wherein the polar solvent comprises ethanol.
18. The composition of claim 12 , wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.
19. The composition of claim 11 , wherein the propellant is selected from the group consisting of propane, N-butane, iso-butane, N-pentane, iso-pentane, neo-pentane, and mixtures thereof.
20. A method of administering ondansetron or a pharmaceutically acceptable salt thereof to a mammal, comprising spraying the oral mucosa of the mammal with the composition of claim 11 .
21. The method of claim 20 , wherein the amount of the spray is predetermined.
22-28. (canceled)
29. An oral spray composition for transmucosal administration of ondansetron or a pharmaceutically acceptable salt thereof comprising: ondansetron or a pharmaceutically acceptable salt thereof in an amount between 0.05 and 50 percent by weight of the total composition; and a non-polar solvent in an amount between 19 and 85 percent by weight of the total composition; and a propellant in an amount between 5 and 80 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or branched configuration.
30. The composition of claim 29 , further comprising a taste mask and/or flavoring agent in an amount of between 0.1 and 10 percent by weight of the total composition.
31. The composition of claim 30 , wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof.
32. An oral spray composition for transmucosal administration of ondansetron or a pharmaceutically acceptable salt thereof comprising: ondansetron or a pharmaceutically acceptable salt thereof in an amount between 0.01 and 40 percent by weight of the total composition; a non-polar solvent in an amount between 25 and 89 percent by weight of the total composition; a propellant in an amount between 10 and 70 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or branched configuration; and a taste mask and/or flavoring agent is present in an amount between 1 and 8 percent by weight of the total composition.
33. The composition of claim 32 , wherein the propellant is present in an amount between 20 and 70 percent by weight of the total composition, the non-polar solvent is present in an amount between 25 and 75 percent by weight of the total composition, the ondansetron or a pharmaceutically acceptable salt thereof is present in an amount from between 0.25 and 35 percent by weight of the total composition, and the taste mask and/or flavoring agent is present in an amount between 2 and 7.5 percent by weight of the total composition.
34. The composition of claim 29 , wherein the propellant is selected from the group consisting of propane, n-butane, iso-butane, n-pentane, iso-pentane, neo-pentane, and mixtures thereof.
35. The composition of claim 34 , wherein the propellant is n-butane or iso-butane and has a water content of not more than 0.2 percent and a concentration of oxidizing agents, reducing agents, Lewis acids, and Lewis bases of less than 0.1 percent.
36. The composition of claim 29 , wherein the solvent is selected from the group consisting of (C2-C24) fatty acid (C2-C6) esters, C7-C18 hydrocarbons of linear or branched configuration, C2-C6 alkanoyl esters, and triglycerides of C2-C6 carboxylic acids.
37. The composition of claim 36 , wherein the solvent is a triglyceride.
38. A method of administering ondansetron or a pharmaceutically acceptable salt thereof to a mammal, comprising spraying the oral mucosa of the mammal with the composition of claim 29 .
39. The method of claim 38 , wherein the amount of the spray is predetermined.
40-48. (canceled)
49. An oral spray composition for transmucosal administration of ondansetron or a pharmaceutically acceptable salt thereof comprising: ondansetron or a pharmaceutically acceptable salt thereof in an amount between 0.05 and 50 percent by weight of the total composition; a mixture of a polar solvent and a non-polar solvent in an amount between 10 and 97 percent by weight of the total composition, wherein the ratio of the polar solvent to the non-polar solvent ranges from 1:99 to 99:1; and a propellant in an amount between 5 and 80 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or branched configuration.
50. The composition of claim 49 , further comprising a taste mask and/or flavoring agent is present in an amount between 0.01 and 10 percent by weight of the total composition.
51. The composition of claim 50 , wherein the propellant is present in an amount between 10 and 70 percent by weight of the total composition, the solvent is present in an amount between 20 and 97 percent by weight of the total composition, the ondansetron or a pharmaceutically acceptable salt thereof is present in an amount from between 0.1 and 40 percent by weight of the total composition, and the taste mask and/or flavoring agent is present in an amount between 1 and 8 percent by weight of the total composition.
52. The composition of claim 49 , wherein the propellant is selected from the group consisting of propane, n-butane, iso-butane, n-pentane, iso-pentane, neo-pentane, and mixtures thereof.
53. The composition of claim 52 , wherein the propellant is n-butane or iso-butane and has a water content of not more than 0.2 percent and a concentration of oxidizing agents, reducing agents, Lewis acids, and Lewis bases of less than 0.1 percent.
54. The composition of claim 49 , wherein the polar solvent is selected from the group consisting of polyethylene glycols having a molecular weight between 400 and 1000, C2 to C8 mono- and poly-alcohols, and C7 to C18 alcohols of linear or branched configuration and the non-polar solvent is selected from the group consisting of (C2-C24) fatty acid (C2-C6) esters, C7-C18 hydrocarbons of linear or branched configuration, C2-C6 alkanoyl esters, and triglycerides of C2-C6 carboxylic acids.
55. A method of administering ondansetron or a pharmaceutically acceptable salt thereof to a mammal, comprising spraying the oral mucosa of the mammal with the composition of claim 49 .
56. The method of claim 55 , wherein the amount of the spray is predetermined.
57-64. (canceled)
65. A method of treating emesis in a patient, comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the spray of claim 11 .
66. The method of claim 65 , wherein the emesis is caused by chemotherapy or radiation.
67. The method of claim 66 , further comprising administering to the patient a corticosteroid.
68. The method of claim 66 , further comprising administering to the patient dexamethasone.
69. The method of claim 66 , wherein the oral mucosa of the patient is sprayed between about 5 minutes and 2 hours before chemotherapy or radiation therapy begins.
70. The method of claim 69 , further comprising spraying the oral mucosa of the patient between about 1 hour and 6 hours after chemotherapy or radiation therapy ends.
71. A method of administering anesthesia to a patient comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the spray of claim 11 before the anesthesia is administered.
72. A method of treating anxiety in a patient, comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the spray of claim 11 .
73-80. (canceled)
81. A method of treating emesis in a patient, comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the spray of claim 29 .
82. The method of claim 81 , wherein the emesis is caused by chemotherapy or radiation.
83. The method of claim 82 , further comprising administering to the patient a corticosteroid.
84. The method of claim 82 , further comprising administering to the patient dexamethasone.
85. The method of claim 82 , wherein the oral mucosa of the patient is sprayed between about 5 minutes and 2 hours before chemotherapy or radiation therapy begins.
86. The method of claim 85 , further comprising spraying the oral mucosa of the patient between about 1 hour and 6 hours after chemotherapy or radiation therapy ends.
87. A method of administering anesthesia to a patient comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the spray of claim 29 before the anesthesia is administered.
88. A method of treating anxiety in a patient, comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the buccal spray of claim 29 .
89-96. (canceled)
97. A method of treating emesis in a patient, comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the spray of claim 49 .
98. The method of claim 97 , wherein the emesis is caused by chemotherapy or radiation.
99. The method of claim 98 , further comprising administering to the patient a corticosteroid.
100. The method of claim 98 , further comprising administering to the patient dexamethasone.
101. The method of claim 98 , wherein the oral mucosa of the patient is sprayed between about 5 minutes and 2 hours before chemotherapy or radiation therapy begins.
102. The method of claim 101 , further comprising spraying the oral mucosa of the patient between about 1 hour and 6 hours after chemotherapy or radiation therapy ends.
103. A method of administering anesthesia to a patient comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the spray of claim 49 before the anesthesia is administered.
104. A method of treating anxiety in a patient, comprising spraying the oral mucosa of the patient with a therapeutically effective amount of the spray of claim 49.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/429,953 US20060198790A1 (en) | 1997-10-01 | 2006-05-09 | Buccal, polar and non-polar spray containing ondansetron |
US12/350,602 US20090162297A1 (en) | 1997-10-01 | 2009-01-08 | Buccal, polar and non-polar spray containing ondansetron |
US13/445,331 US9078816B2 (en) | 1997-10-01 | 2012-04-12 | Buccal, polar and non-polar spray containing ondansetron |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1997/017899 WO1999016417A1 (en) | 1997-10-01 | 1997-10-01 | Buccal, polar and non-polar spray or capsule |
US53711800A | 2000-03-29 | 2000-03-29 | |
US10/230,085 US20030095926A1 (en) | 1997-10-01 | 2002-08-29 | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US10/671,717 US20040136914A1 (en) | 1997-10-01 | 2003-09-29 | Buccal, polar and non-polar spray containing ondansetron |
US11/429,953 US20060198790A1 (en) | 1997-10-01 | 2006-05-09 | Buccal, polar and non-polar spray containing ondansetron |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/671,717 Division US20040136914A1 (en) | 1997-10-01 | 2003-09-29 | Buccal, polar and non-polar spray containing ondansetron |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/350,602 Continuation US20090162297A1 (en) | 1997-10-01 | 2009-01-08 | Buccal, polar and non-polar spray containing ondansetron |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060198790A1 true US20060198790A1 (en) | 2006-09-07 |
Family
ID=34422011
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/671,717 Abandoned US20040136914A1 (en) | 1997-10-01 | 2003-09-29 | Buccal, polar and non-polar spray containing ondansetron |
US11/429,953 Abandoned US20060198790A1 (en) | 1997-10-01 | 2006-05-09 | Buccal, polar and non-polar spray containing ondansetron |
US12/350,602 Abandoned US20090162297A1 (en) | 1997-10-01 | 2009-01-08 | Buccal, polar and non-polar spray containing ondansetron |
US12/632,719 Abandoned US20100152262A1 (en) | 1997-10-01 | 2009-12-07 | Buccal, polar and non-polar spray containing ondansetron |
US13/445,331 Expired - Fee Related US9078816B2 (en) | 1997-10-01 | 2012-04-12 | Buccal, polar and non-polar spray containing ondansetron |
US13/450,987 Abandoned US20120202866A1 (en) | 1997-10-01 | 2012-04-19 | Buccal, polar and non-polar spray containing ondansetron |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/671,717 Abandoned US20040136914A1 (en) | 1997-10-01 | 2003-09-29 | Buccal, polar and non-polar spray containing ondansetron |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/350,602 Abandoned US20090162297A1 (en) | 1997-10-01 | 2009-01-08 | Buccal, polar and non-polar spray containing ondansetron |
US12/632,719 Abandoned US20100152262A1 (en) | 1997-10-01 | 2009-12-07 | Buccal, polar and non-polar spray containing ondansetron |
US13/445,331 Expired - Fee Related US9078816B2 (en) | 1997-10-01 | 2012-04-12 | Buccal, polar and non-polar spray containing ondansetron |
US13/450,987 Abandoned US20120202866A1 (en) | 1997-10-01 | 2012-04-19 | Buccal, polar and non-polar spray containing ondansetron |
Country Status (7)
Country | Link |
---|---|
US (6) | US20040136914A1 (en) |
EP (1) | EP1682090A1 (en) |
JP (1) | JP2007507509A (en) |
KR (1) | KR20060090997A (en) |
CA (1) | CA2554954A1 (en) |
IL (1) | IL174623A0 (en) |
WO (1) | WO2005032520A1 (en) |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20030095927A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20030190286A1 (en) * | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US20040062716A1 (en) * | 1997-10-01 | 2004-04-01 | Novadel Pharma Inc. | Buccal, polar and non-polar spray of capsule |
US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
US20040141923A1 (en) * | 1997-10-01 | 2004-07-22 | Dugger Harry A. | Buccal, polar and non-polar spray containing alprazolam |
US20050025715A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
US20050180923A1 (en) * | 1997-10-01 | 2005-08-18 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing testosterone |
US20050281752A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20050287075A1 (en) * | 1997-10-01 | 2005-12-29 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20060165604A1 (en) * | 1997-10-01 | 2006-07-27 | Dugger Harry A Iii | Buccal, polar and non-polar spray containing sumatriptan |
US20060216240A1 (en) * | 1997-10-01 | 2006-09-28 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US20060222597A1 (en) * | 1997-10-01 | 2006-10-05 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
US20080171089A1 (en) * | 2006-12-22 | 2008-07-17 | Blondino Frank E | Stable anti-nausea oral spray formulations and methods |
US20080280947A1 (en) * | 2007-05-10 | 2008-11-13 | Blondino Frank E | Anti-insomnia compositions and methods |
US20090162300A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing alprazolam |
US20090162297A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing ondansetron |
US20100298397A1 (en) * | 2009-05-19 | 2010-11-25 | Singh Nikhilesh N | Method of treatment of obsessive compulsive disorder with ondansetron |
WO2011090694A1 (en) * | 2009-12-28 | 2011-07-28 | Monosol Rx, Llc | Orally administrable film dosage forms containing ondansetron |
US8652378B1 (en) | 2001-10-12 | 2014-02-18 | Monosol Rx Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8906277B2 (en) | 2001-10-12 | 2014-12-09 | Monosol Rx, Llc | Process for manufacturing a resulting pharmaceutical film |
US9108340B2 (en) | 2001-10-12 | 2015-08-18 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US9198867B2 (en) | 2008-01-09 | 2015-12-01 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
WO2016004409A1 (en) * | 2014-07-03 | 2016-01-07 | Luxena Pharmaceuticals, Inc. | Novel aerosol formulations of ondansetron and uses thereof |
US9393207B2 (en) | 2006-10-09 | 2016-07-19 | Locl Pharma, Inc. | Pharmaceutical compositions |
US9433625B2 (en) | 2009-07-08 | 2016-09-06 | Locl Pharma, Inc. | Pharmaceutical compositions for treating or preventing pain |
US9770409B2 (en) | 2013-07-03 | 2017-09-26 | Luxena Pharmaceuticals, Inc. | Aerosol formulations of ondansetron and uses thereof |
US10179109B2 (en) | 2016-03-04 | 2019-01-15 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates |
US10272607B2 (en) | 2010-10-22 | 2019-04-30 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US10821074B2 (en) | 2009-08-07 | 2020-11-03 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US11077068B2 (en) | 2001-10-12 | 2021-08-03 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US11191737B2 (en) | 2016-05-05 | 2021-12-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140104986A (en) * | 2004-02-17 | 2014-08-29 | 트랜스셉트 파마슈티칼스, 인코포레이티드 | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
US20060127472A1 (en) * | 2004-12-13 | 2006-06-15 | Keith Whitehead | Taste-masked prednisolone oral formulations |
AU2006214166B2 (en) | 2005-02-17 | 2011-09-29 | Zoetis Belgium S.A. | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
US20070123562A1 (en) * | 2005-05-25 | 2007-05-31 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the-night insomnia |
RU2432950C2 (en) | 2006-01-25 | 2011-11-10 | Инсис Терапьютикс Инк. | Sublingual fentanyl-based spray |
WO2007123955A2 (en) * | 2006-04-19 | 2007-11-01 | Novadel Pharma Inc. | Stable hydroalcoholic oral spray formulations and methods |
CA2659245A1 (en) * | 2006-07-28 | 2008-01-31 | Novadel Pharma Inc. | Anti-migraine oral spray formulations and methods |
ES2325339T3 (en) * | 2006-10-24 | 2009-09-01 | Helsinn Healthcare S.A. | SOFT CAPSULES THAT INCLUDE PALONOSETRON HYDROCHLORIDE THAT HAVE IMPROVED STABILITY AND BIODISPONIBILITY. |
PL2180844T3 (en) | 2007-08-02 | 2018-07-31 | Insys Development Company, Inc. | Sublingual fentanyl spray |
US7985325B2 (en) * | 2007-10-30 | 2011-07-26 | Novellus Systems, Inc. | Closed contact electroplating cup assembly |
FR2940120B1 (en) | 2008-12-19 | 2012-07-13 | Philippe Perovitch | FORMULATION FOR TRANSMUCOSAL DELIVERY OF SETRONS |
JP6227304B2 (en) * | 2013-07-04 | 2017-11-08 | キリン株式会社 | Ornithine or salt derived masking method |
EP3068376A4 (en) * | 2013-11-14 | 2017-06-07 | Insys Pharma, Inc. | Ondansetron sublingual spray formulation |
US10324922B2 (en) * | 2014-02-13 | 2019-06-18 | Salesforce.Com, Inc. | Providing a timeline of events regarding a database record |
US10172833B2 (en) * | 2015-08-11 | 2019-01-08 | Insys Development Company, Inc. | Sublingual ondansetron spray |
AU2017351744A1 (en) | 2016-10-31 | 2019-05-02 | Suda Ltd | Mucosal active agent delivery |
Citations (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155574A (en) * | 1962-05-24 | 1964-11-03 | Revlon | Aerosol composition |
US3304230A (en) * | 1963-02-18 | 1967-02-14 | Revlon | Liquid aerosol propellant solutions of fatty acid salts of physiologically active amines |
US3784684A (en) * | 1971-08-24 | 1974-01-08 | Bayer Ag | Coronary dilator in a pharmaceutical dosage unit form |
US4232002A (en) * | 1977-12-01 | 1980-11-04 | The Welsh National School Of Medicine | Procedures and pharmaceutical products for use in the administration of antihistamines |
US4495168A (en) * | 1983-08-22 | 1985-01-22 | Basf Wyandotte Corporation | Aerosol gel |
US4689233A (en) * | 1986-01-06 | 1987-08-25 | Siegfried Aktiengesellschaft | Coronary therapeutic agent in the form of soft gelatin capsules |
US4704406A (en) * | 1985-06-24 | 1987-11-03 | Klinge Pharma Gmbh | Sprayable pharmaceutical composition for topical use |
US4755389A (en) * | 1985-09-11 | 1988-07-05 | Lilly Industries Limited | Chewable capsules |
US4814161A (en) * | 1985-01-16 | 1989-03-21 | Riker Laboratories, Inc. | Drug-containing chlorofluorocarbon aerosol propellent formulations |
US4857312A (en) * | 1985-12-18 | 1989-08-15 | Bayer Aktiengesellschaft | Dihydropyridine spray, process for its preparation and its pharmaceutical use |
US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
US4863720A (en) * | 1986-03-10 | 1989-09-05 | Walter Burghart | Pharmaceutical preparation and methods for its production |
US4919919A (en) * | 1987-09-30 | 1990-04-24 | Nippon Kayaku Kabushiki Kaisha | Nitroglycerin spray |
US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
US5047230A (en) * | 1988-07-08 | 1991-09-10 | Egis Gyogyszergyar | Aerosol composition comprising nitroglycerin as active ingredient |
US5128132A (en) * | 1988-11-22 | 1992-07-07 | Parnell Pharmaceuticals, Inc. | Eriodictyon compositions and methods for treating internal mucous membranes |
US5135753A (en) * | 1991-03-12 | 1992-08-04 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
US5143731A (en) * | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
US5166145A (en) * | 1990-09-10 | 1992-11-24 | Alza Corporation | Antiemetic therapy |
US5186925A (en) * | 1990-03-10 | 1993-02-16 | G. Pohl-Boskamp Gmbh & Co. | Nitroglycerin pump spray |
US5240932A (en) * | 1990-03-30 | 1993-08-31 | Yasunori Morimoto | Percutaneously absorbable compositions of morphine or analogous analgesics of morphine |
US5290540A (en) * | 1991-05-01 | 1994-03-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method for treating infectious respiratory diseases |
US5364616A (en) * | 1992-04-15 | 1994-11-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
US5428006A (en) * | 1990-05-10 | 1995-06-27 | Bechgaard International Research And Development A/S | Method of administering a biologically active substance |
US5457100A (en) * | 1991-12-02 | 1995-10-10 | Daniel; David G. | Method for treatment of recurrent paroxysmal neuropsychiatric |
US5456677A (en) * | 1994-08-22 | 1995-10-10 | Spector; John E. | Method for oral spray administration of caffeine |
US5502076A (en) * | 1994-03-08 | 1996-03-26 | Hoffmann-La Roche Inc. | Dispersing agents for use with hydrofluoroalkane propellants |
US5519059A (en) * | 1994-08-17 | 1996-05-21 | Sawaya; Assad S. | Antifungal formulation |
US5593684A (en) * | 1993-08-04 | 1997-01-14 | Pharmacia Ab | Method and therapeutic system for smoking cessation |
US5602182A (en) * | 1995-01-30 | 1997-02-11 | American Home Products Corporation | Taste masking pseudoephedrine HCL containing liquids |
US5605674A (en) * | 1988-12-06 | 1997-02-25 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5607915A (en) * | 1992-09-29 | 1997-03-04 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
US5635161A (en) * | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
US5645856A (en) * | 1994-03-16 | 1997-07-08 | R. P. Scherer Corporation | Delivery systems for hydrophobic drugs |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5725841A (en) * | 1993-03-17 | 1998-03-10 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
US5766573A (en) * | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US5824307A (en) * | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5869082A (en) * | 1996-04-12 | 1999-02-09 | Flemington Pharmaceutical Corp. | Buccal, non-polar spray for nitroglycerin |
US5891465A (en) * | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
US5906811A (en) * | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
US5908611A (en) * | 1995-05-05 | 1999-06-01 | The Scripps Research Institute | Treatment of viscous mucous-associated diseases |
US5955098A (en) * | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
US5981591A (en) * | 1992-12-04 | 1999-11-09 | Mayor Pharmaceutical Laboratories, Inc. | Sprayable analgesic composition and method of use |
US6071539A (en) * | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
US6110486A (en) * | 1996-04-12 | 2000-08-29 | Flemington Pharmaceuticals Co. | Buccal polar spray or capsule |
US6143329A (en) * | 1996-07-03 | 2000-11-07 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
US6212227B1 (en) * | 1997-12-02 | 2001-04-03 | Conexant Systems, Inc. | Constant envelope modulation for splitterless DSL transmission |
US6258032B1 (en) * | 1997-01-29 | 2001-07-10 | William M. Hammesfahr | Method of diagnosis and treatment and related compositions and apparatus |
US6271240B1 (en) * | 1996-05-06 | 2001-08-07 | David Lew Simon | Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals |
US6299900B1 (en) * | 1996-02-19 | 2001-10-09 | Monash University | Dermal penetration enhancers and drug delivery systems involving same |
US6375975B1 (en) * | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
US20020102218A1 (en) * | 2000-12-01 | 2002-08-01 | Cowan Siu Man L. | Stable, aerosolizable suspensions of proteins in ethanol |
US6458842B1 (en) * | 1994-02-01 | 2002-10-01 | Knoll Aktiengesellschaft | Liquid pharmaceutical compositions comprising thyroid hormones |
US6512002B2 (en) * | 2000-01-12 | 2003-01-28 | Pfizer Inc. | Methods of treatment for premature ejaculation in a male |
US20030039680A1 (en) * | 1997-10-01 | 2003-02-27 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20030077228A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
US20030095927A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20030191180A1 (en) * | 2000-03-09 | 2003-10-09 | Calvin Ross | Pharmaceutical compositions |
US20030190286A1 (en) * | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US20040136914A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
US20040136913A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing sumatriptan |
US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
US20040141923A1 (en) * | 1997-10-01 | 2004-07-22 | Dugger Harry A. | Buccal, polar and non-polar spray containing alprazolam |
US20050002867A1 (en) * | 1997-10-01 | 2005-01-06 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
US20050180923A1 (en) * | 1997-10-01 | 2005-08-18 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing testosterone |
US20060159624A1 (en) * | 1997-10-01 | 2006-07-20 | Dugger Harry A Iii | Buccal, polar and non-polar spray containing zolpidem |
US7202233B2 (en) * | 2000-03-28 | 2007-04-10 | Farmarc Nederland Bv | Alprazolam inclusion complexes and pharmaceutical compositions thereof |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA815698B (en) | 1980-08-28 | 1983-04-27 | Lilly Co Eli | Intranasal formulation |
DE3338978A1 (en) | 1982-10-29 | 1984-05-03 | Basf Ag, 6700 Ludwigshafen | Verapamil and gallopamil and their physiologically tolerated salts for application onto the mucous membranes of the mouth, of the naso-pharyngeal space and of the rectum for absorption |
DE3246081A1 (en) | 1982-12-13 | 1984-06-14 | G. Pohl-Boskamp GmbH & Co Chemisch-pharmazeutische Fabrik, 2214 Hohenlockstedt | Nitroglycerin spray |
IT1169873B (en) | 1983-10-21 | 1987-06-03 | Prodotti Formenti Srl | PHARMACEUTICAL COMPOSITION WITH SYSTEMIC ANTI-COLINESTERASIC, AGONISTIC-COLINERGIC AND ANTI-MUSCARINIC ACTIVITY |
EP0213108A3 (en) | 1985-06-26 | 1987-07-15 | Kurt Dr. Burghart | Pharmaceutical preparation containing an antihypotonic as the active agent |
DE3738236A1 (en) | 1987-11-11 | 1989-05-24 | Euro Celtique Sa | BIT CAPSULE |
WO1989010745A1 (en) | 1988-05-02 | 1989-11-16 | Pomerantz, Edwin | Compositions and in situ methods for forming films on body tissue |
US5428066A (en) * | 1989-03-08 | 1995-06-27 | Larner; Joseph | Method of reducing elevated blood sugar in humans |
DE3907414A1 (en) | 1989-03-08 | 1990-09-13 | Hoechst Ag | THE APPLICATION OF INHALED LOOP DIURETICS FOR THE TREATMENT OF ALLERGEN-INDUCED NASAL REACTIONS |
US5370862A (en) * | 1990-06-13 | 1994-12-06 | Schwarz Pharma Ag | Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina |
DE4026072A1 (en) | 1990-08-17 | 1992-02-20 | Sanol Arznei Schwarz Gmbh | NITROGLYCER-CONTAINING, HYDROPHILIC, WAESSRING PUMPSPRAY |
DE4038203A1 (en) | 1990-11-30 | 1992-06-04 | Kali Chemie Pharma Gmbh | Pharmaceutical spray-prepn. for admin. of nitrate(s) - esp. for treatment of cardiovascular, disorders, asthma, migraine and colic |
EP0504112A3 (en) | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
DE4112303A1 (en) | 1991-04-15 | 1992-10-22 | Minnesota Mining & Mfg | Nitroglycerin, propellant gas-free spray prepn. - stored in container in which the steel parts are made of V4A series steels to inhibit nitroglycerin decomposition |
DE69231994T3 (en) | 1991-06-10 | 2010-01-21 | Schering Corp. | Chlorofluorocarbon-free aerosol formulations |
ATE197126T1 (en) * | 1991-08-26 | 2000-11-15 | Abbott Lab | COMPOUNDS AND METHODS FOR SUBLINGUAL OR BUCCAL ADMINISTRATION OF THERAPEUTIC AGENTS |
GB9118830D0 (en) | 1991-09-03 | 1991-10-16 | Minnesota Mining & Mfg | Medical aerosol formulations |
DE4132176C2 (en) | 1991-09-27 | 1997-03-13 | Ig Spruehtechnik Gmbh | Metered aerosols with isobutane as propellant |
DK0557129T3 (en) | 1992-02-20 | 1997-04-14 | Wielligh Johannes Louw Kot Von | Product to help smokers quit smoking |
AU5551394A (en) | 1992-11-09 | 1994-06-08 | Pharmetrix Corporation | Combined analgesic delivery methods for pain management |
JPH07506839A (en) * | 1992-12-04 | 1995-07-27 | メイヤー・ファーマシューティカル・ラボラトリース・インコーポレーテッド | Sprayable analgesic compositions and methods of use thereof |
CA2189351C (en) * | 1994-05-13 | 2008-12-30 | Stephen J. Farr | Narcotic containing aerosol formulation |
GB9409778D0 (en) | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
GB9423511D0 (en) * | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
NZ280610A (en) | 1994-12-29 | 1997-08-22 | Mcneil Ppc Inc | Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent |
JPH0967248A (en) * | 1995-08-30 | 1997-03-11 | Takada Seiyaku Kk | Preparation adhering to mucous membrane of oral cavity |
AUPN862596A0 (en) | 1996-03-12 | 1996-04-04 | F.H. Faulding & Co. Limited | Pharmaceutical compositions |
ZA9711732B (en) | 1996-12-31 | 1998-12-28 | Quadrant Holdings Cambridge | Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery |
DK1014943T3 (en) | 1997-02-05 | 2002-10-14 | Jago Res Ag | Medical aerosol formulations |
AU8107998A (en) | 1997-05-22 | 1998-12-11 | Boots Company Plc, The | Pharmaceutical compositions |
AU7916798A (en) | 1997-05-22 | 1998-12-11 | Boots Company Plc, The | Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat |
US20090162300A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing alprazolam |
US20050281752A1 (en) | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20050287075A1 (en) | 1997-10-01 | 2005-12-29 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6167501A (en) * | 1998-06-05 | 2000-12-26 | Billions Of Operations Per Second, Inc. | Methods and apparatus for manarray PE-PE switch control |
ATE295347T1 (en) | 1998-07-27 | 2005-05-15 | Emisphere Tech Inc | SUBSTANCES AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES |
JP2002529393A (en) | 1998-11-12 | 2002-09-10 | フランク ジー. ピルキーウィッツ, | Inhalation system |
GB9908921D0 (en) | 1999-04-19 | 1999-06-16 | Britannia Pharmaceuticals Ltd | Spray dispenser for opiod antagonists |
JP3127918B1 (en) * | 1999-07-14 | 2001-01-29 | 住友電気工業株式会社 | Road-to-vehicle communication system, roadside communication station and on-vehicle mobile station |
US6585957B1 (en) | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
WO2001059142A1 (en) | 2000-02-09 | 2001-08-16 | Medimmune, Inc. | Antibody gene therapy with adeno-associated viral vectors |
JP3589167B2 (en) * | 2000-08-28 | 2004-11-17 | 住友電装株式会社 | connector |
JP4505186B2 (en) | 2000-11-13 | 2010-07-21 | ザ プロクター アンド ギャンブル カンパニー | Dispersible absorbent product, its production and use |
WO2002094232A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of antidepressants through an inhalation route |
DE60231611D1 (en) | 2001-05-24 | 2009-04-30 | Alexza Pharmaceuticals Inc | ADMINISTRATION OF OPIOIDES BY INHALATION |
US6685951B2 (en) * | 2001-07-05 | 2004-02-03 | R. T. Alamo Ventures I, Inc. | Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine |
US7039104B2 (en) * | 2002-11-08 | 2006-05-02 | Scintera Networks, Inc. | Adaptive coefficient signal generator for adaptive signal equalizers with fractionally-spaced feedback |
AU2006214166B2 (en) | 2005-02-17 | 2011-09-29 | Zoetis Belgium S.A. | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
-
2003
- 2003-09-29 US US10/671,717 patent/US20040136914A1/en not_active Abandoned
-
2004
- 2004-09-27 KR KR1020067008480A patent/KR20060090997A/en not_active Application Discontinuation
- 2004-09-27 JP JP2006534019A patent/JP2007507509A/en active Pending
- 2004-09-27 WO PCT/US2004/031801 patent/WO2005032520A1/en active Application Filing
- 2004-09-27 EP EP04789153A patent/EP1682090A1/en not_active Ceased
- 2004-09-27 CA CA002554954A patent/CA2554954A1/en not_active Abandoned
-
2006
- 2006-03-29 IL IL174623A patent/IL174623A0/en unknown
- 2006-05-09 US US11/429,953 patent/US20060198790A1/en not_active Abandoned
-
2009
- 2009-01-08 US US12/350,602 patent/US20090162297A1/en not_active Abandoned
- 2009-12-07 US US12/632,719 patent/US20100152262A1/en not_active Abandoned
-
2012
- 2012-04-12 US US13/445,331 patent/US9078816B2/en not_active Expired - Fee Related
- 2012-04-19 US US13/450,987 patent/US20120202866A1/en not_active Abandoned
Patent Citations (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155574A (en) * | 1962-05-24 | 1964-11-03 | Revlon | Aerosol composition |
US3304230A (en) * | 1963-02-18 | 1967-02-14 | Revlon | Liquid aerosol propellant solutions of fatty acid salts of physiologically active amines |
US3784684A (en) * | 1971-08-24 | 1974-01-08 | Bayer Ag | Coronary dilator in a pharmaceutical dosage unit form |
US4232002A (en) * | 1977-12-01 | 1980-11-04 | The Welsh National School Of Medicine | Procedures and pharmaceutical products for use in the administration of antihistamines |
US4495168A (en) * | 1983-08-22 | 1985-01-22 | Basf Wyandotte Corporation | Aerosol gel |
US4814161A (en) * | 1985-01-16 | 1989-03-21 | Riker Laboratories, Inc. | Drug-containing chlorofluorocarbon aerosol propellent formulations |
US4704406A (en) * | 1985-06-24 | 1987-11-03 | Klinge Pharma Gmbh | Sprayable pharmaceutical composition for topical use |
US4755389A (en) * | 1985-09-11 | 1988-07-05 | Lilly Industries Limited | Chewable capsules |
US4857312A (en) * | 1985-12-18 | 1989-08-15 | Bayer Aktiengesellschaft | Dihydropyridine spray, process for its preparation and its pharmaceutical use |
US4689233A (en) * | 1986-01-06 | 1987-08-25 | Siegfried Aktiengesellschaft | Coronary therapeutic agent in the form of soft gelatin capsules |
US4863720A (en) * | 1986-03-10 | 1989-09-05 | Walter Burghart | Pharmaceutical preparation and methods for its production |
US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
US4919919A (en) * | 1987-09-30 | 1990-04-24 | Nippon Kayaku Kabushiki Kaisha | Nitroglycerin spray |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5047230A (en) * | 1988-07-08 | 1991-09-10 | Egis Gyogyszergyar | Aerosol composition comprising nitroglycerin as active ingredient |
US5128132A (en) * | 1988-11-22 | 1992-07-07 | Parnell Pharmaceuticals, Inc. | Eriodictyon compositions and methods for treating internal mucous membranes |
US5766573A (en) * | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5605674A (en) * | 1988-12-06 | 1997-02-25 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
US5186925A (en) * | 1990-03-10 | 1993-02-16 | G. Pohl-Boskamp Gmbh & Co. | Nitroglycerin pump spray |
US5240932A (en) * | 1990-03-30 | 1993-08-31 | Yasunori Morimoto | Percutaneously absorbable compositions of morphine or analogous analgesics of morphine |
US5428006A (en) * | 1990-05-10 | 1995-06-27 | Bechgaard International Research And Development A/S | Method of administering a biologically active substance |
US5143731A (en) * | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
US5166145A (en) * | 1990-09-10 | 1992-11-24 | Alza Corporation | Antiemetic therapy |
US5135753A (en) * | 1991-03-12 | 1992-08-04 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
US5290540A (en) * | 1991-05-01 | 1994-03-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method for treating infectious respiratory diseases |
US5457100A (en) * | 1991-12-02 | 1995-10-10 | Daniel; David G. | Method for treatment of recurrent paroxysmal neuropsychiatric |
US5824307A (en) * | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5364616A (en) * | 1992-04-15 | 1994-11-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
US5607915A (en) * | 1992-09-29 | 1997-03-04 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
US5981591A (en) * | 1992-12-04 | 1999-11-09 | Mayor Pharmaceutical Laboratories, Inc. | Sprayable analgesic composition and method of use |
US5725841A (en) * | 1993-03-17 | 1998-03-10 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
US5593684A (en) * | 1993-08-04 | 1997-01-14 | Pharmacia Ab | Method and therapeutic system for smoking cessation |
US6458842B1 (en) * | 1994-02-01 | 2002-10-01 | Knoll Aktiengesellschaft | Liquid pharmaceutical compositions comprising thyroid hormones |
US6706255B2 (en) * | 1994-02-01 | 2004-03-16 | Abbott Gmbh & Co., Kg | Liquid pharmaceutical compositions comprising thyroid hormones |
US5502076A (en) * | 1994-03-08 | 1996-03-26 | Hoffmann-La Roche Inc. | Dispersing agents for use with hydrofluoroalkane propellants |
US5645856A (en) * | 1994-03-16 | 1997-07-08 | R. P. Scherer Corporation | Delivery systems for hydrophobic drugs |
US5519059A (en) * | 1994-08-17 | 1996-05-21 | Sawaya; Assad S. | Antifungal formulation |
US5456677A (en) * | 1994-08-22 | 1995-10-10 | Spector; John E. | Method for oral spray administration of caffeine |
US5602182A (en) * | 1995-01-30 | 1997-02-11 | American Home Products Corporation | Taste masking pseudoephedrine HCL containing liquids |
US5908611A (en) * | 1995-05-05 | 1999-06-01 | The Scripps Research Institute | Treatment of viscous mucous-associated diseases |
US5635161A (en) * | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
US6299900B1 (en) * | 1996-02-19 | 2001-10-09 | Monash University | Dermal penetration enhancers and drug delivery systems involving same |
US5955098A (en) * | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
US5869082A (en) * | 1996-04-12 | 1999-02-09 | Flemington Pharmaceutical Corp. | Buccal, non-polar spray for nitroglycerin |
US6110486A (en) * | 1996-04-12 | 2000-08-29 | Flemington Pharmaceuticals Co. | Buccal polar spray or capsule |
US6271240B1 (en) * | 1996-05-06 | 2001-08-07 | David Lew Simon | Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals |
US5891465A (en) * | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6143329A (en) * | 1996-07-03 | 2000-11-07 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
US6071539A (en) * | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
US6258032B1 (en) * | 1997-01-29 | 2001-07-10 | William M. Hammesfahr | Method of diagnosis and treatment and related compositions and apparatus |
US5906811A (en) * | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
US20040120895A1 (en) * | 1997-10-01 | 2004-06-24 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20050142069A1 (en) * | 1997-10-01 | 2005-06-30 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20070048229A1 (en) * | 1997-10-01 | 2007-03-01 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing atropine |
US20040136913A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing sumatriptan |
US20030039680A1 (en) * | 1997-10-01 | 2003-02-27 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20030077228A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
US20040136914A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
US20060222597A1 (en) * | 1997-10-01 | 2006-10-05 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
US20030190286A1 (en) * | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US6676931B2 (en) * | 1997-10-01 | 2004-01-13 | Novadel Pharma Inc. | Buccal, polar and non-polar spray or capsule |
US20060216240A1 (en) * | 1997-10-01 | 2006-09-28 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US20040062716A1 (en) * | 1997-10-01 | 2004-04-01 | Novadel Pharma Inc. | Buccal, polar and non-polar spray of capsule |
US20040120896A1 (en) * | 1997-10-01 | 2004-06-24 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20060216241A1 (en) * | 1997-10-01 | 2006-09-28 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing diazepam |
US20030095927A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
US20060210484A1 (en) * | 1997-10-01 | 2006-09-21 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing testosterone |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20040141923A1 (en) * | 1997-10-01 | 2004-07-22 | Dugger Harry A. | Buccal, polar and non-polar spray containing alprazolam |
US20050002867A1 (en) * | 1997-10-01 | 2005-01-06 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
US20050025714A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
US20050025715A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
US20050025712A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US20050025716A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20050025717A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
US20050025713A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US20060171896A1 (en) * | 1997-10-01 | 2006-08-03 | Dugger Harry A Iii | Buccal, polar and non-polar spray containing alprazolam |
US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
US20050180923A1 (en) * | 1997-10-01 | 2005-08-18 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing testosterone |
US6998110B2 (en) * | 1997-10-01 | 2006-02-14 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule |
US20060159624A1 (en) * | 1997-10-01 | 2006-07-20 | Dugger Harry A Iii | Buccal, polar and non-polar spray containing zolpidem |
US20060165604A1 (en) * | 1997-10-01 | 2006-07-27 | Dugger Harry A Iii | Buccal, polar and non-polar spray containing sumatriptan |
US6212227B1 (en) * | 1997-12-02 | 2001-04-03 | Conexant Systems, Inc. | Constant envelope modulation for splitterless DSL transmission |
US6375975B1 (en) * | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
US6512002B2 (en) * | 2000-01-12 | 2003-01-28 | Pfizer Inc. | Methods of treatment for premature ejaculation in a male |
US20030191180A1 (en) * | 2000-03-09 | 2003-10-09 | Calvin Ross | Pharmaceutical compositions |
US7202233B2 (en) * | 2000-03-28 | 2007-04-10 | Farmarc Nederland Bv | Alprazolam inclusion complexes and pharmaceutical compositions thereof |
US20020110524A1 (en) * | 2000-12-01 | 2002-08-15 | Cowan Siu Man L. | Method for stabilizing biomolecules in liquid formulations |
US20020102218A1 (en) * | 2000-12-01 | 2002-08-01 | Cowan Siu Man L. | Stable, aerosolizable suspensions of proteins in ethanol |
Cited By (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20030095927A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20030190286A1 (en) * | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US20040062716A1 (en) * | 1997-10-01 | 2004-04-01 | Novadel Pharma Inc. | Buccal, polar and non-polar spray of capsule |
US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
US20040141923A1 (en) * | 1997-10-01 | 2004-07-22 | Dugger Harry A. | Buccal, polar and non-polar spray containing alprazolam |
US20050025715A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
US20050025716A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20050025714A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
US20050025717A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
US20050025712A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US20050025713A1 (en) * | 1997-10-01 | 2005-02-03 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US20050142069A1 (en) * | 1997-10-01 | 2005-06-30 | Novadel Pharma, Inc. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
US20050180923A1 (en) * | 1997-10-01 | 2005-08-18 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing testosterone |
US20050281752A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20050281753A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule |
US20050287075A1 (en) * | 1997-10-01 | 2005-12-29 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20060165604A1 (en) * | 1997-10-01 | 2006-07-27 | Dugger Harry A Iii | Buccal, polar and non-polar spray containing sumatriptan |
US20060171896A1 (en) * | 1997-10-01 | 2006-08-03 | Dugger Harry A Iii | Buccal, polar and non-polar spray containing alprazolam |
US20060210484A1 (en) * | 1997-10-01 | 2006-09-21 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing testosterone |
US20060216240A1 (en) * | 1997-10-01 | 2006-09-28 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US20060222597A1 (en) * | 1997-10-01 | 2006-10-05 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
US20070048229A1 (en) * | 1997-10-01 | 2007-03-01 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing atropine |
US20090118170A1 (en) * | 1997-10-01 | 2009-05-07 | Dugger Iii Harry A | Buccal, polar and non-polar spray or capsule |
US20090162298A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing sumatriptan |
US20090162300A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing alprazolam |
US20090162297A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing ondansetron |
US20100092403A1 (en) * | 1997-10-01 | 2010-04-15 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing zolpidem |
US8236285B2 (en) | 1997-10-01 | 2012-08-07 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US9078816B2 (en) | 1997-10-01 | 2015-07-14 | Suda Ltd. | Buccal, polar and non-polar spray containing ondansetron |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US9931305B2 (en) | 2001-10-12 | 2018-04-03 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US9855221B2 (en) | 2001-10-12 | 2018-01-02 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8906277B2 (en) | 2001-10-12 | 2014-12-09 | Monosol Rx, Llc | Process for manufacturing a resulting pharmaceutical film |
US8652378B1 (en) | 2001-10-12 | 2014-02-18 | Monosol Rx Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US9108340B2 (en) | 2001-10-12 | 2015-08-18 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US10888499B2 (en) | 2001-10-12 | 2021-01-12 | Aquestive Therapeutics, Inc. | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
US11077068B2 (en) | 2001-10-12 | 2021-08-03 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US10111810B2 (en) | 2002-04-11 | 2018-10-30 | Aquestive Therapeutics, Inc. | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
US9393207B2 (en) | 2006-10-09 | 2016-07-19 | Locl Pharma, Inc. | Pharmaceutical compositions |
US9399022B2 (en) | 2006-10-09 | 2016-07-26 | Locl Pharma, Inc. | Pharmaceutical compositions |
US9402813B2 (en) | 2006-10-09 | 2016-08-02 | Locl Pharma, Inc. | Pharmaceutical compositions |
US9427407B2 (en) | 2006-10-09 | 2016-08-30 | Locl Pharma, Inc. | Pharmaceutical compositions |
US20080171089A1 (en) * | 2006-12-22 | 2008-07-17 | Blondino Frank E | Stable anti-nausea oral spray formulations and methods |
US20080280947A1 (en) * | 2007-05-10 | 2008-11-13 | Blondino Frank E | Anti-insomnia compositions and methods |
US20110040266A1 (en) * | 2007-05-10 | 2011-02-17 | Blondino Frank E | Anti-insomnia compositions and methods |
US9198867B2 (en) | 2008-01-09 | 2015-12-01 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
US9498444B2 (en) | 2008-01-09 | 2016-11-22 | Locl Pharma, Inc. | Pharmaceutical compositions |
US10064856B2 (en) | 2008-01-09 | 2018-09-04 | Local Pharma, Inc. | Pharmaceutical compositions |
US9775837B2 (en) | 2008-01-09 | 2017-10-03 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
US9789104B2 (en) | 2008-01-09 | 2017-10-17 | Locl Pharma, Inc. | Pharmaceutical compositions |
US9789105B2 (en) | 2008-01-09 | 2017-10-17 | Locl Pharma, Inc. | Pharmaceutical compositions |
US9855264B2 (en) | 2008-01-09 | 2018-01-02 | Locl Pharma, Inc. | Pharmaceutical compositions |
US9226901B2 (en) | 2008-01-09 | 2016-01-05 | Locl Pharma, Inc. | Pharmaceutical compositions |
US9387177B2 (en) | 2008-01-09 | 2016-07-12 | Locl Pharma, Inc. | Pharmaceutical compositions |
US20100298397A1 (en) * | 2009-05-19 | 2010-11-25 | Singh Nikhilesh N | Method of treatment of obsessive compulsive disorder with ondansetron |
US10016368B2 (en) | 2009-07-08 | 2018-07-10 | Locl Pharma, Inc. | Pharmaceutical compositions for treating or preventing pain |
US9433625B2 (en) | 2009-07-08 | 2016-09-06 | Locl Pharma, Inc. | Pharmaceutical compositions for treating or preventing pain |
US9526704B2 (en) | 2009-07-08 | 2016-12-27 | Locl Pharma, Inc. | Pharmaceutical compositions for treating or preventing pain |
US10532030B2 (en) | 2009-07-08 | 2020-01-14 | Locl Pharma, Inc. | Pharmaceutical compositions for treating or preventing pain |
US10821074B2 (en) | 2009-08-07 | 2020-11-03 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
WO2011090694A1 (en) * | 2009-12-28 | 2011-07-28 | Monosol Rx, Llc | Orally administrable film dosage forms containing ondansetron |
US10940626B2 (en) | 2010-10-22 | 2021-03-09 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
US10272607B2 (en) | 2010-10-22 | 2019-04-30 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
US9770409B2 (en) | 2013-07-03 | 2017-09-26 | Luxena Pharmaceuticals, Inc. | Aerosol formulations of ondansetron and uses thereof |
WO2016004409A1 (en) * | 2014-07-03 | 2016-01-07 | Luxena Pharmaceuticals, Inc. | Novel aerosol formulations of ondansetron and uses thereof |
US10772840B2 (en) | 2016-03-04 | 2020-09-15 | Charleston Laboratories, Inc. | Sumatriptan promethazine pharmaceutical compositions |
US10179109B2 (en) | 2016-03-04 | 2019-01-15 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates |
US11191737B2 (en) | 2016-05-05 | 2021-12-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
Also Published As
Publication number | Publication date |
---|---|
CA2554954A1 (en) | 2005-04-14 |
EP1682090A1 (en) | 2006-07-26 |
KR20060090997A (en) | 2006-08-17 |
WO2005032520A1 (en) | 2005-04-14 |
IL174623A0 (en) | 2006-08-20 |
US20120295945A1 (en) | 2012-11-22 |
US20120202866A1 (en) | 2012-08-09 |
US20090162297A1 (en) | 2009-06-25 |
US9078816B2 (en) | 2015-07-14 |
US20040136914A1 (en) | 2004-07-15 |
US20100152262A1 (en) | 2010-06-17 |
JP2007507509A (en) | 2007-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9078816B2 (en) | Buccal, polar and non-polar spray containing ondansetron | |
US6998110B2 (en) | Buccal, polar and non-polar spray or capsule | |
US6969508B2 (en) | Buccal, polar and non-polar spray or capsule containing drugs for treating pain | |
US20050025716A1 (en) | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract | |
US20030095927A1 (en) | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders | |
US20050025712A1 (en) | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma | |
US20090162298A1 (en) | Buccal, polar and non-polar spray containing sumatriptan | |
US20050287075A1 (en) | Buccal, polar and non-polar spray or capsule containing drugs for treating pain | |
EP1444976A1 (en) | Buccal, polar and non-polar spray or capsule |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PROQUEST INVESTMENTS III, L.P. AS COLLATERAL AGENT Free format text: SECURITY AGREEMENT;ASSIGNOR:NOVADEL PHARMA INC.;REEL/FRAME:021029/0574 Effective date: 20080506 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NOVADEL PHARMA INC., NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:PROQUEST INVESTMENTS III, L.P. AS COLLATERAL AGENT;REEL/FRAME:024915/0277 Effective date: 20100830 |